

2007 Annual report ESRD clinical performance measures project. (<http://www.cms.gov/CPMProject/Downloads/ESRDCPMYear2007Report.pdf>; accessed 3/20/2001)

2008 Annual report ESRD clinical performance measures project. (<http://www.esrdnetwork.org/assets/pdf/data/2008cpmanualreport.pdf>; accessed 3/20/2001)

42nd Annual Meeting of the Drug Information Association. June 19, 2006. Patient-reported outcome instruments: overview and comments on the FDA draft guidance. <http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm118795.pdf>.

AABB. Circular of information for the use of human blood and blood components. Revised December 2009. (Accessed March 2011 at <http://www.aabb.org/resources/bct/Documents/coi0809r.pdf>).

Aalten J, Bemelman FJ, van den Berg-Loonen EM, Claas FH, Christianns MH, de Fijter JW, et al. Pre-kidney-transplant blood transfusions do not improve transplantation outcome: a Dutch national study. *Nephrol Dial Transplant*. 2009;24:2559-2566.

Aarup M, Bryndum J, Dieperink H, Joffe P. Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. *Nephrol Dial Transplant*. 2006;21:1312-1316.

Abdu A, Arogundade F, Adamu B, Dutse AI, Sanusi A, Sani MU, et al. Anaemia and its response to treatment with recombinant human erythropoietin in chronic kidney disease patients. *West Afr Med*. 2009;28(5):295-299.

Abdulahdi MH, Fouad-Tarazi FM, Thomas T, Bravo EL, Paganini EP. The haemodynamic effects of correction of anaemia in haemodialysis patients using recombinant human erythropoietin. *Nephrol Dial Transplant*. 1990;5 Suppl1:102-108.

Abe M, Okada K, Soma M, Matsumoto K. Relationship between insulin resistance and erythropoietin responsiveness in hemodialysis patients. *Clin Nephrol*. 2011;75(1):49-58.

Abels R. Rate of progression of chronic renal failure in predialysis patients treated with erythropoietin. *Semin Nephrol*. 1990;10(2)Suppl 1:20-25.

Aberman A, Hew E. Clarification of the effects of changes in P50 on oxygen transport. *Acute Care*. 1985;11:216-221.

Abraham PA. Practical approach to initiation of recombinant human erythropoietin therapy and prevention and management of adverse effects. *Am J Nephrol*. 1990;10(suppl 2):7-14.

Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *J Am Soc Nephrol*. 1991;2:927-936.

Abraham PA, Opsahl JA, Keshaviah PR, Collins AJ, Whalen JJ, Asinger RW, et al. Body fluid spaces and blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. *Am J Kidney Dis*. 1990;16(5):438-446.

Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. *Am J Nephrol*. 1990;10:128-136.

Abraham PA, St Peter WL, Redic-Kill KA, Halstenson CE. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. *Clin Pharmacokinet*. 1992;22(6):409-415.

Abu-Alfa, AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. *Am J Kidney Dis*. 2000;35(6):1076-1082.

Abu-Alfa AK, Sloan L, Charytan C, Sekkarie M, Scarlatt D, Globe D, Audhya P. The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysis. *Curr Med Res Opin*. 2008;24(4):1091-1100.

Acchiardo SR, Quinn BP, Burk LB, Moore LW. Are high flux dialysis and erythropoietin treatment in a collision course? *ASAIO Trans*. 1989;35:308-310.

Acchiardo SR, Quinn BP, Moore LW, Burk LB, Miles DE. Evaluation of hemodialysis patients treated with erythropoietin. *Am J Kidney Dis*. 1991;17(3):290-294.

Adamson JW. The promise of recombinant human erythropoietin. *Semin Hematol*. 1989;26(2)Suppl 2:5-8.

Adamson JW, Eschbach J. Erythropoietin for end-stage renal disease. *N Engl J Med*. 1998;339(9):624-629.

Adamson JW, Eschbach J. Management of the anaemia of chronic renal failure with recombinant erythropoietin. *QJ Med*. 1989;272(73):1093-1101.

Adamson W, Egrie JC, Browne JK, Downing MR, Eschbach W. The use of recombinant human erythropoietin (EPO) to correct the anemia of end-stage renal disease: a progress report. *Behring Inst Mitt*. 1988;83:188-192.

Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. *Clin J Am Soc Nephrol*. 2008;3(1):98-104.

Agarwal R, Rizkala AR, Kaskas MO, Minasian R, Trout JR. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. *Kidney*. 2007;72:638-642.

Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. *Semin Nephrol*. 2002;22(6):479-487.

Agency for Healthcare Research and Quality National Health Care Disparities Report. U.S. Dept of Health and Human Services. AHRQ publication No. 11-0005. February 2011.

Affarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. *J Assoc Physicians India*. 2003;51:170-174.

Agoram B, Aoki K, Doshi S, Gegg C, Jang G, Molineux G, et al. Investigation of the effects of altered receptor binding activity on the clearance of erythropoiesis-stimulating proteins: nonerythropoietin receptor-mediated pathways may play a major role. *J Pharm Sci*. 2009;98(6):2198-2211.

Akada H, Yan D, Zou H, Fiering S, Hutchinson RE, Mohi G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera like disease. *Blood*. 2010;115:3589-3597.

Akarsu S, Taskin E, Yilmaz E, Yilmaz H, Kilic M, Aygun AD. Treatment of iron deficiency anemia with intravenous iron preparations. *Acta Haematol*. 2006;1161:51-57.

Aktekin LA, Eser F, Malhan S, Öksüz E, Keskin D, Bodur H. A comparison of four different HRQoL generic questionnaires in five different patient groups. *Rheumatol Int*. 2009;30:63-67.

Akinci F, Yildirim A, Ogutman B, Ates M, Gozu H, Deyneli O, et al. Translation, cultural adaptation, initial reliability, and validation of Turkish 15d's version. *Eval Health Prof*. 2005;28(1):53-66.

Akizawa T, Koshikawa S, Iwasaki M, and the KRN321 A08 Study Group. Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. *Ther Apher Dial*. 2007;11(3):220-226.

Al-Hilali N, Al-Humoud H, Ninan VT, Nampoory MRN, Puliyclil MA, Johny KV. Does parathyroid hormone affect erythropoietin therapy in dialysis patients? *Med Princ Pract*. 2007;16:63-67.

Al-Muzairai IA, Innes A, Hillis A, Stewart KN, Bone JM, Catto GR, Macleod AM. Renal transplantation: cyclosporine A and antibody development after donor-specific transfusion. *Kidney*. 1989;35:1057-1063.

Alam MG, Krause MW, Shah SV. Parental iron therapy: beyond anaphylaxis. *Kidney*. 2004;66:457-458.

Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L. Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study. *Int J Artif Organs*. 1998;21(1):12-18.

Albitar S, Genin R, Fen-Chong M, Serveaux M, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. *Nephrol Dial Transplant*. 1998;13:1206-1210.

Albrechtsen D, Flatmark A, Lundgren G, Brynger H, Frödin, Groth CG, Gäbel H. Retransplantation of renal grafts: prognostic influence of previous transplantation. *Transplant Proc*. 1987;19(5):3619-3621.

Alcázar R, Tato A, García F, Barrios V, Quereda C. [Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?] *Nefrologia*. 2010;30(1):114-118.

Alexander JW, Babcock GF, First MR, Davies CB, Madden RL, Munda R, et al. The induction of immunologic hyporesponsiveness by preoperative donor-specific transfusions and cyclosporine in human cadaveric transplants. *Transplantation*. 1992;53(2):423-427.

Alexander M, Kewalramani R, Agodoa I, Globe D. Association of anemia correction with health related quality of life in patients not on dialysis. *Curr Med Res Opin*. 2007;23(12):2997-3008.

Alexanian R. Erythropoietin excretion in bone marrow failure and hemolytic anemia. *J Lab Clin Med*. 1973;82(3):438-445.

Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Olson K, et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. *Clin Pharmacol Ther*. 2002;72:546-555.

Alter HJ, Klein HG. The hazards of blood transfusion in historical perspective. *Blood*. 2008;112(7):2617-2626.

Amar M, Cendoroglo Neto M, Canziani MEF, Nadaletto MAJ, Ajzen H, Draibe SA. Correction of anemia in chronic renal failure with lyophilized recombinant human erythropoietin using a subcutaneous approach. *Rev Ass Med Bras*. 1994;40(2):101-107.

American Association of Blood Banks. Standards for Blood Banks and Transfusion Services. 27th Edition. 2011.

Anaemia Management in Chronic Kidney Disease. Rapid Update 2011 (Original publication 2006) Commissioned by the National Institute for Health and Clinical Excellence (NICE). Published by the National Clinical Guideline Centre (NCGC) at the Royal College of Physicians, London, UK.

Anandh U, Thomas PP, Shastry JCM, Jacob CK. A randomized controlled trial of intradermal hepatitis B vaccination and augmentation of response with erythropoietin. *J Assoc Physicians India*. 2000;48:1061-1063.

Anderson CB, Brennan D, Keller C, Goss J, Shenoy S, Burton K, Sicard G, Fiye MW. Beneficial effects of donor-specific transfusions on long-term renal allograft function. *Transplant Proc*. 1989;21:1828-1831.

Anderson CB, Jendrisak MD, Flye MW, Hanto DW, Anderman CK, Rodey GE, Sicard GA. Concomitant immunosuppression and donor-specific transfusions prior to renal transplantation. *Transplant Proc*. 1989;21(1):1828-1831.

Andrassy K, Ritz E. Uremia as a cause of bleeding. *Am J Nephrol*. 1985;5:313-319.

André J, Deschênes G, Boudailliez B, Broux F, Fischbach M, Gagnadoux M, et al. Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure. *Pediatr Nephrol*. 2007;22:708-714.

- Ansell D. UK Renal Registry 11th Annual Report (Dec 2008): Chapter 1 Summary of findings in the 2008 UK renal registry report. *Nephron Clin Pract.* 2009;111(Suppl1):c1-2.
- Ansell D. UK Renal Registry 11th Annual Report: Chapter 2 Introduction to the 2008 UK Renal Registry Report. *Nephron Clin Pract.* 2009;111 (Suppl1):c3-c12.
- Arabul M, Gullulu M, Yilmaz Y, Eren MA, Baran B, Gul CB, et al. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients. *Med Sci Monit.* 2009;15(11):CR583-587.
- Arcasoy MO, Jiang X. Co-operative signaling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. *Br J Haematol.* 2005;130:121-129.
- Arneson T, Dunning S, Gilbertson DT, Collins AJ. Elimination of racial disparity in hemoglobin level in dialysis patients: a result of EPO dose? *Am Soc Nephrol.* 2007 (Accessed March 2011 at http://www.cdrp.org/pub_pres/files/2007/16A_asn07_race_hgb_epo_dose.pdf).
- Aronoff GR, Bennett WM, Blumenthal S, Charytan C, Pennell JP, Reed J, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. *Kidney Int.* 2004;66:1193-1198.
- Aronoff GR, Duff DR, Sloan RS, Brier ME, Maurice B, Erickson B, Golper TA. The treatment of anemia with low-dose recombinant human erythropoietin. *Am J Nephrol.* 1990;10(Suppl 2):40-43.
- Asbury CH. The orphan drug act: the first 7 years. *JAMA.* 1991;265(7):893-897.
- Astor BC, Muntner P, Levin A, Eustace JA, Coresh J. Association of kidney function with anemia. The third national health and nutrition examination survey (1988-1994). *Arch Intern Med.* 2002;162:1401-1408.
- Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. *Am J Kidney Dis.* 2006;47(4):644-654.
- Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. *Lancet.* 2007;369:1502-1504.
- Aunsholt NA, Ahlbom G, Steffensen G, Glud T. Fibrinolytic capacity in hemodialysis patients treated with recombinant human erythropoietin. *Nephron.* 1992;62:284-288.
- Axelsson J, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P, Bárány P. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. *Am J Kidney Dis.* 2005; 46(40):628-634.
- Ayli D, Ayli M, Azak A, Yüksel C, Kosmaz GP, Atilgan G, et al. The effect of high-flux hemodialysis on renal anemia. *J Nephrol.* 2004;17:701-706.
- Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, et al. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL. *Kidney Int.* 2005;68(2):788-795.
- Bader R, Bode G, Rebel W, Lexa P. Stimulation of bone marrow by administration of excessive doses of recombinant human erythropoietin. *Path Res Pract.* 1992;188:676-679.
- Bahlmann J, Schöter KH, Scigalla P, Gurland HJ, Hilfenhaus M, Koch KM, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: a controlled study. *Contrib Nephrol.* 1991;88:90-106.
- Baillie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. *Nephrol Dial Transplant.* 2005;20:1443-1449.
- Baillie GR, Low CL, Eisele G. Erythropoietin effectiveness index: a quantitative definition of resistance in haemodialysis patients with adequate iron stores. *Clin Drug Invest.* 1998;15(1):57-60.
- Baj Z, Pokoca L, Majewska E, Luciak M, Tchórzewski H. T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment. *Arch Immunol Ther Exp (Warsz).* 1992;40:201-206.
- Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. *Am J Kidney Dis.* 1991;17(1):29-33.
- Bambola O. Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations. *Pediatr Nephrol.* 2011;11.
- Bambola OF, Kaskel FJ, Coco M. Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. *Pediatr Nephrol.* 2009;24:571-579.
- Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. *Nephrol Dial Transplant.* 2001;16:224-227.
- Bárány P, Filho JCD, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. *Am J Kidney Dis.* 1997;29(4):565-568.
- Barber WH, Hudson SL, Deierhoi MH, Laskow DA, Gaston RS, Julian BA, Curtis JJ, Diethelm AG. Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients. *Clin Transpl.* 1990;289-300.
- Bargman JN, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. *Perit Dial Int.* 1992;12:369-372.

Barosi G, Hoffman R. Idiopathic myelofibrosis. *Semin Hematol.* 2005;42:248-258.

Bastani B. Selective disappearance of donor-specific antibodies and absence of acute rejection after liver transplantation in a patient with a strongly positive lymphocyte crossmatch. *Arch Iranian Med.* 2006;9(2):163-164.

Bastani B, Rahman S, Gellens M. Lack of reaction to ferric gluconate in hemodialysis patients with a history of severe reaction to iron dextran. *ASAIO J.* 2002;48:404-406.

Beauregard P, Blajchman MA. Hemolytic and pseudo-hemolytic transfusion reactions: an overview of the hemolytic transfusion reactions and the clinical conditions that mimic them. *Trans Med Rev.* 1994;8(3):184-199.

Bedani PL, Verzola A, Bergami M, Stabellini G, Gilli P. Erythropoietin and cardiocirculatory condition in aged patients with chronic renal failure. *Nephron.* 2001;89:350-353.

Beguini Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G. Early prediction of response to response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. *Blood.* 1993;82:2010-2016.

Bellizzi V, Minutolo R, Terracciano V, Iodice C, Giannattasio P, De Nicola L, et al. Influence of the cyclic variation of hydration status on hemoglobin levels in hemodialysis patients. *Am J Kidney Dis.* 2002;40(3):549-555.

Belonje AM, Voors AA, van der Meer P, van Gilst WH, Jaarsma T, van Veldhuisen DJ. Endogenous erythropoietin and outcome in heart failure. *Circulation.* 2010;121:245-251.

Bennett CL, Lai SY, Henke M, Barnato SE, Armitage JO, Sartor O. Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. *Arch Intern Med.* 2010;170(16):1490-1498.

Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. *J Am Soc Nephrol.* 1991;1:990-998.

Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. *Clin J Am Soc Nephrol.* 2007;2:215-221.

Berger A, Mamzer-Bruneel MF, Legendre C, Cugnenc PH, Kreis H. Segmental necrosis of the ascending colon in haemodialysis patients. *Nephrol Dial Transplant.* 1995;10(12):2281-2285.

Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. *Med Care.* 1981;19(8):787-805.

Bergner M, Bobbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. *Int J Health Serv.* 1976;6(3):393-415.

Berns JS, Rudnick MR, Cohen RM. A controlled trial of recombinant human erythropoietin and nandrolone decanoate in the treatment of anemia in patients on chronic hemodialysis. *Clin Nephrol.* 1992;37(5):264-267.

Berns JS, Rudnick MR, Cohen RM, Bower JD, Wood BC. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. *Kidney.* 1999;56:253-260.

Berridge MV, Fraser JK, Carter JM, Lin F. Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. *Blood.* 1988;72(3):970-977.

Berthoux F, Rychelynck JP, Rouanet S, Gelu-Mantoulet S, Montestruc F, Mouchel P, Choukroun G. A trial comparing local pain after subcutaneous injection of epoetin- β versus darbepoetin- α in healthy volunteers. *Clin Nephrol.* 2008;70(1):33-40.

Besarab A, Medina F, Musial E, Picarello N, Michael H. Recombinant human erythropoietin does not increase clotting in vascular accesses. *ASAIO Trans.* 1990;36:M749-M753.

Besarab A, Flaharty KK, Erslev AJ, McCrea JB, Vlases PH, Medina F, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous in end-stage renal disease: the case for subcutaneous administration. *J Am Soc Nephrol.* 1992;2:1405-1416.

Besarab A, McCrea JB. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. *ASAIO J.* 1993;39(1):11-18.

Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med.* 1998;339(9):584-590.

Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. *Am J Kidney Dis.* 2002;40(3):439-446.

Besarab A. Resolving the paradigm crisis in intravenous iron and erythropoietin management. *Kidney.* 2006;69:S13-S18.

Besarab A, Salifu MO, Lunde NM, Bansal V, Fishbane S, Dougherty FC, Beyer U. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease. *Clin Ther.* 2007;29(4):626-639.

Besarab A, Goodkin DA, Nissenson AR. The normal hematocrit study—follow up. *N Engl J Med.* 2008;358(4):433-434.

Besarab A, Frinak S, Yee J. What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway? *Adv Chronic Kidney Dis.* 2009;16(2):131-142.

Besarab A, Hörl WH, Silverberg D. Iron metabolism, iron deficiency, thrombocytosis and the cardio-renal anemia syndrome. *Oncologist*. 2009;17(Suppl 1):22-33.

Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. *Nat Rev Nephrol*. 2010;6:699-710.

Besarab A, Yee L. Candidate biomarkers of erythropoietin response in hemodialysis patients. *Kidney Int*. 2011;79(5):488-490.

Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE. The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. *J Am Soc Nephrol*. 1996;7:763-773.

Bia MJ, Cooper K, Schnall S, Duffy T, Hendler E, Malluche H, Solomon L. Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis. *Kidney Int*. 1989;36:852-858.

Bini EJ, Kinkhabwala A, Goldfarb DS. Predictive value of a positive fecal occult blood test increases as the severity of CKD worsens. *Am J Kidney Dis*. 2006;48(4):580-586.

Biolo G, Guarnieri G, Barazzoni R, Panzetta G. Complete correction of anemia by erythropoiesis-stimulating agents is associated with insulin resistance in emodialysis patients. *Clin Exp Med*. 2010;7.

Birgegård G, Hällgren R, Caro J. Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of anti-inflammatory treatment. *Br J Haematol*. 1987;65:479-483.

Bishu K, Agarwal R. Acute injury with intravenous iron and concerns regarding long-term safety. *Clin J Am Soc Nephrol*. 2006;1:S19-S23.

Blajchman MA. Landmark studies that have changed the practice of Transfus Med. *Transfusion*. 2005;45:1523-1530.

Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. *N Engl J Med*. 2006;355:1303-1305.

Ble A, Fink JC, Woodman RC, Klausner MA, Windham BG, Guralnik JM, Ferrucci L. Renal function, erythropoietin, and anemia of older persons. *Arch Intern Med*. 2005;165:2222-2227.

Bloodbook. Transfusion transmitted diseases. <http://bloodbook.com/trans-tran.html>. Accessed March 30, 2011.

Bock HA, Hirt-Minkowski P, Brünisholz M, Keusch G, Rey S, von Albertini B. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. *Nephrol Dial Transplant*. 2008;23:301-308.

Boddana P, Caskey F, Casula A, Ansell D. Chapter 14: UK Renal Registry and international comparisons. *Nephron Clin Pract*. 2009;111(suppl 1):c269-276.

Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. *Nephrol Dial Transplant*. 1990;5:130-134.

Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, Bogaert MG. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients. *Perit Dial Int*. 1989;9:95-98.

Bommer J, Asmus G, Wenning M, Bommer G. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alpha: a German prospective, randomized, multicentre study. *Nephrol Dial Transplant*. 2008;23:4002-4008.

Bommer J, Kugel M, Schoeppe W, Brunkhorst R, Samtleben W, Bramsiepe P, Scigalla P. Dose-related effects of recombinant human erythropoietin on erythropoiesis. *Contrib Nephrol*. 1988;66:85-93.

Bommer J, Samtleben W, Koch KM, Baldamus CA, Grützmacher P, Scigalla P. Variations of recombinant human erythropoietin application in hemodialysis patients. *Contrib Nephrol*. 1989;76:149-158.

Boran M, Dalva I, Yazicioğlu A, Cetin S. Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients. *Nephron*. 1993;63:113-114.

Bou-Habib JC, Krams S, Colombe BW, Bubar OT, Yousif B, Amend WJC, et al. Impaired kidney graft survival in flow cytometric crossmatched positive donor-specific transfusion recipients. *Transplant Proc*. 1991;23(1):403-404.

Boudville NC, Djurdjev O, Macdougall IC, de Francisco ALM, Deray G, Besarab A, et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. *Clin J Am Soc Nephrol*. 2009;4:1176-1182.

Bovean K, Knight J, Bader F, Rossert J, Eckardt K, Casadevall N. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. *Nephrol Dial Transplant*. 2005;20[Suppl 3]:iii33-iii40.

Boven K, Stryker S, Knight J, Thomas A, van Regenmortel M, Kemeny DM, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. *Kidney Int*. 2005;67:2346-2353.

Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. *Clin J Am Soc Nephrol*. 2009;4:630-637.

Bradbury BD, Do TP, Winkelmayr WC, Critchlow CW, Brookhart MA. Greater epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL. *Pharmacoeconom Drug Saf*. 2009;18:932-940.

- Bradbury BD, Wang O, Critchlow CW, Rothman KJ, Heagerty P, Keen M, Acquavella JF. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. *Am J Kidney Dis.* 2008;51(1):62-70.
- Brandt JR, Avner ED, Hickman RO, Watkins SL. Safety and efficacy of erythropoietin in children with chronic renal failure. *Pediatr Nephrol.* 2000;14(1):84-5.
- Brațescu LO, Bârsan L, Munteanu D, Stancu S, Mircescu G. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients? *J Renal Nutr.* 2010;20(5S):S77-S83.
- Braun WE. Update on kidney transplantation: increasing clinical success, expanding waiting lists. *Cleve Clin J Med.* 2002;69(6):501-504.
- Brenner BM, Rector FC, Eds. *Brenner and Rector's The Kidney.* First edition. Philadelphia: WB Saunders. 1976.
- Brenner BM, Rector FC, Eds. *Brenner and Rector's The Kidney.* Second edition. Philadelphia: WB Saunders. 1981.
- Brenner BM, Levine SA, Eds. *Brenner and Rector's The Kidney.* Eighth edition. Philadelphia: WB Saunders. 2008.
- Brewster US, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. *Semin Dial.* 2004;17(1):57-60.
- Breyman C, Rohling R, Huch A, Huch R. Intraoperative endogenous erythropoietin levels and changes in intravenous blood volume in healthy humans. *Ann Hematol.* 2000;79:183-186.
- Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA. Randomized trial of model predictive control for improved anemia management. *Clin J Am Soc Nephrol.* 2010;5:814-820.
- Brockmüller J, Köchling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. *Br J Clin Pharmacol.* 1992;34:499-508.
- Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayr WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. *JAMA* 2010;303(9):857-862.
- Brosnahan G, Fraer M. Management of chronic kidney disease: what is the evidence? *South Med J.* 2010;10(20):1-9.
- Brown S, Caro J, Erslev AJ, Murray TG. Spontaneous increase in erythropoietin and hematocrit value associated with transient liver enzyme abnormalities in an anephric patient undergoing hemodialysis. *Am J Med.* 1980;68:280-284.
- Brown CD, Zhao ZH, Thomas LL, deGroof R, Friedman EA. Effects of erythropoietin and aminoguanidine on red blood cell deformability in diabetic azotemic and uremic patients. *Am J Kidney Dis.* 2001;38(6):1414-1420.
- Buckingham JE. Human recombinant erythropoietin does not induce bone marrow fibrosis in haemodialysed patients. *Nephrol Dial Transplant.* 1989;4:674-679.
- Buemi M, Allegra A, Laganá A, Aloisi C, Privitera M, Morabito N, Frisina N. Effects of the evening IV administration of erythropoietin in haemodialyzed patients. *Riv Eur Sci Med Farmacol.* 1993;15:195-197.
- Burgess ED. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. *Am J Nephrol.* 1991;23-26.
- Buur T, Lundberg M. Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. *Clin Nephrol.* 1990;34(3):230-235.
- Callero MA, Vota DM, Chamorro ME, Wenker SD, Vittori DC, Nesse AB. Calcium as a mediator between erythropoietin and protein tyrosine phosphatase 1B. *Arch Biochem Biophys.* 2011;505:242-249.
- Cambridge GW, McDonald FF. The influence of diet on the acute toxicity of injectable iron preparations in the mouse. *Br J Pharmac Chemother.* 1966;27:114-119.
- Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. *Nephrol Dial Transplant.* 1999;17(suppl 2):61-65.
- Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. *Br Med J.* 1990;300:573-578.
- Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients. *Am J Nephrol.* 1991;11:23-26.
- Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, et al. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. *Nephrol Dial Transplant.* 2008;23:3654-3661.
- Caravaca F, López-Minguez R, Arrobas M, Cubero J, Pizarro JL, Cid MC, et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. *Nephrol Dial Transplant.* 1995;10:1720-1724.
- Cardiovascular and renal drugs advisory committee (CRDAC) in joint session with drug safety and risk management advisory committee (DSARM) meeting. Sept 11, 2007. Gaithersburg, MD.
- Carless PA, Henry DA, Carson JL, Herbert PPC, McClelland B, Ker K. Transfusion thresholds and other strategies for guiding allogenic red blood cell transfusion (Review). *Cochrane Database of Systematic Reviews* 2010, Issue 10.
- Caro J, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer. *Cancer.* 2001;91:2214-2221.

- Caro J, Erslev AJ. Erythropoietin assays and their use in the study of anemias. *Contrib Nephrol.* 1988;66:54-62.
- Carozzi S, Nasini MG, Santoni O, Tirota A, Sanna A. Recombinant human erythropoietin resistance in hemodialysis. *ASAIO J.* 1997;43(5):M535-538.
- Carracedo J, Madueno JA, Ramirez R, Martin-Malo A, de Francisco AL, Aljama P. Antibody-mediated pure red-cell aplasia (PRCA): the Spanish experience. *J Nephrol.* 2005;18:382-387.
- Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JFE, Canaud B, et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene a glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. *Nephrol Dial Transplant.* 2010;25:4009-4017.
- Carrera F, Oliveira L, Maia P, Mendes T, Ferreira C. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis. *Nephrol Dial Transplant.* 2006;21:2846-2850.
- Carson JL, Altman DG, Duff A, Noveck H, Weinstein MP, Sonnenberg FA, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. *Transfusion.* 1999;39:694-700.
- Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. *Transfusion.* 2002;42:812-818.
- Carson JL, Terrin ML, Magaziner J, Chaitman BR, Apple FS, Heck DA, Sanders D. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). *Transfusion.* 2006;46(12):2192-2206.
- Carson JL, Reynolds RC, Klein HG. Bad bad blood? *Crit Care Med.* 2008;36(9):2707-2708.
- Carter WB, Bobbitt RA, Bergner M, Gilson BS. Validation of an interval scaling: the sickness impact profile. *Health Serv Res.* 1976:516-528.
- Casadevall N. Cellular mechanism of resistance to erythropoietin. *Nephrol Dial Transplant.* 1995;10(S6):27-30.
- Case DC, Bukowski RM, Carey RW, Fishkin EH, Henry DH, Jacobson RJ, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. *J Natl Cancer Inst.* 1993;85(10):801-806.
- Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. *Blood.* 1988;71:305-312.
- Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney AP. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. *Nephrology.* 2005;10:129-135.
- Cetinkaya R, Odabas AR, Selcuk Y, Erman Z, Kaya H. Bone marrow amyloidosis with erythropoietin-resistant anemia in a patient undergoing chronic hemodialysis treatment. *South Med J.* 2003;96(5):491-493.
- Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. *Am J Kidney Dis.* 2001;38(5):988-991.
- Charnow JA. Hemoglobin levels linked to vitamin D in diabetic CKD patients. 2009 Oct [cited 2009 Oct 31];[2 pgs.]. Available from: <http://www.renalandneurologynews.com/hemoglobin-levels-linked-to-vitamin-D-in-diabetic-CKD-patients/>.
- Charnow JA. Wasting, inflammation hike death risk in dialysis patients with EPO resistance. 2009 Oct [cited 2009 Oct 31];[1 p.]. Available from: <http://www.renalandneurologynews.com/wasting-inflammation-hike-death-risk-in-dialysis-patients-with-EPO-resistance/>.
- Charnow JA. Anemia hikes long-term mortality in non-diabetic CKD patients. 2009 Nov [cited 2009 Nov 1];[2 pgs.]. Available from: <http://www.renalandneurologynews.com/anemia-hikes-long-term-mortality-in-non-diabetic-CKD-patients/>.
- Charnow JA. Why large doses of IV iron decreases HD patient survival is unclear. 2009 Nov [cited 2009 Nov];[1 p.]. Available from: <http://www.renalandneurologynews.com/why-large-doses-of-IV-iron-decreases-HD-patient-survival-is-unclear/>.
- Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. *Nephron Clin Pract.* 2004;96:c63-c66.
- Chavers BM, Sullivan EK, Tejani A, Harmon WE. Pre-transplant blood transfusion and renal allograft outcome: a report of the north American pediatric renal transplant cooperative study. *Pediatr Transplant.* 1997;1:22-28.
- Chazot C, Terrat JC, Dumoulin A, Ang K, Gassia JP, Chedid K, Maurice F, Canaud B. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. *Ann Pharmacother.* 2009;43:228-234.
- Cheigh JS, Suthanthiran M, Stubenbord WT, Fotino M, Riggio RR, Schechter N, Stenzel KH, Rubin AL. Optimization of donor specific blood transfusion in kidney transplantation. *Transplant Proc.* 1987;19(1):2250-2251.
- Chen H, Tarnag D, Lee K, Wu C, Chen Y. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. *J Nephrol.* 2008;21:543-549.
- Chew CG, Weise MD, Disney APS. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. *Nephrol Dial Transplant.* 1999;14:2047-2049.
- Chong ZZ, Kang J, Maiese K. Angiogenesis and plasticity: role of erythropoietin in vascular system. *J Hematother Stem Cell Res.* 2002;11:863-871.
- Churchill DN, Taylor DW, Cook RJ, Math M, LaPlante P, Barre P. Canadian Hemodialysis Morbidity Study. *Am J Kidney Dis.* 1992;19(3):214-234.

- Churchill DN, Torrance GW, Taylor DW, Barnes CC, Ludwin D, Shimizu A, Smith EKM. Measurement of quality of life in end-stage renal disease: the time trade-off approach. *Clin Invest Med.* 1987;10(1):14-20.
- Clement FM, Klarenbach S, Tonelli M, Johnson JA, Manns BJ. The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease. *Arch Intern Med.* 169(12):1104-1112.
- Clibon U, Bonewald L, Caro J, Roodman D. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. *Exp Hematol.* 1990;18:438-441.
- Clinical Performance Measures (CPM) Project. http://www.cms.gov/cpmproject/01_overview.asp. Accessed March 30, 2011.
- Clyne N, Jogstrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. *Nephron.* 1992;60:390-396.
- Cody JD, Daly C, Campbell MK, Khan I, Radindranath KS, Vale L, Wallace SA, MacLeod AM, Grant A, Pennington S. Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis (review). *Cochrane Database of Systematic Reviews* 2009, Issue 3.
- Cofán F, Bonal J, Castellote E, Caralps A. Vasculitis in haemodialysis : a new form of resistance to erythropoietin. *Nephrol Dial Transplant.* 1993;8(6):569-570
- Cohen D, Raia RM. Erythropoietin (EPO) requirements remain high in EPO resistant patients after iron repletion. *ASAIO J.* 1998;44:M596-M597.
- Collart FE, Dratwa M, Wittek M, Wens R. Effects of recombinant human erythropoietin on T lymphocyte subsets in hemodialysis patients. *ASAIO Trans.* 1990;36(3):M219-223.
- Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. *Semin Nephrol.* 2000;20(4):345-349.
- Collins AJ, Ma JZ, Xia A, Ebben J. Trends in anemia treatment with erythropoietin usage and patient outcomes. *Am J Kidney Dis.* 1998;32(6)(Suppl 4):S133-S141.
- Congote LF, Sadvakassova G, Dobocan MC, DiFalco MR, Li Q. Erythropoietin-dependent endothelial proteins: potential use against erythropoietin resistance. *Cytokine.* 2010;51:113-118.
- Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. *renal failure.* 2000;22(4):435-444.
- Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, MacDougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN- γ , TNF- α , IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. *J Am Soc Nephrol.* 2003;14:1776-1784.
- Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. *JAMA.* 2007;298(17):2038-2047.
- Corwin HL. Anemia and red blood cell transfusion in the critically ill. *Semin Dial.* 2006;19(6):513-516.
- Corwin HL. The role of erythropoietin therapy in the critically ill. *Trans Med Rev.* 2006;20(1):27-33.
- Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, et al. Efficacy and safety of epoetin alfa in critically ill patients. *NEMJ.* 2007;357(10):965-976.
- Costa E, Rocha S, Rocha-Pereira P, Castro E, Miranda V, do Sameiro Faria M, et al. Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. *Blood Purif.* 2008;26:267-273.
- Coster JM. Recombinant erythropoietin: orphan product with a silver spoon. *Int J Technol Assess HealthCare.* 1992;8(4):635-646.
- Cotes PM, Pippard MJ, Reid CDL, Winearls CG, Oliver DO, Royston JP. Characterization of the anaemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. *QJ Med.* 1989;70(262):113-137.
- Coyne DW, Sims A, Bingel B. Results of an anemia management program to reduce high Epoetin® doses by targeted use of IV ferric gluconate. *Nephrol Nurse J.* 2008;35(6):583-587.
- Crawley J. Iron absorption tests in anaemia: the use of intravenous iron preparations. *Edinburgh Medical Journal.* 1952;59(10):478-491.
- Cruz DN, de Calm, Garzotto F, Brendolan A, Nalesso F, Corradi V, Ronco C. Effect of vitamin E-coated dialysis membranes on anemia in patients with chronic kidney disease: an Italian multicenter study. *Int J Artif Organs.* 2008;31(6):545-552.
- Cruz DN, de Cal M, Ronco C (eds): Hemodialysis-from basic research to clinical trials. *Contrib Nephrol.* Basel, Karger, 2008, vol 161, pp 89-98.
- Cruz DN, Perazella MA, Abu-Alfa AK, Mahnensmith RL. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance? *Am J Kidney Dis.* 1996;28(4):535-540.
- Daniell HW. Erythropoietin resistance during androgen deficiency. *Arch Intern Med.* 2006;166:1923-1924.
- Dar Santos AE, Shalansky KF, Jastrzebski JP. Management of anemia in erythropoietin-resistant hemodialysis patients. *Ann Pharmacother.* 2003;37(12):1768-1773.
- Davies CB, Alexander JW, Cofer BR, First MR, Schroeder TJ. Efficacy of a single pretransplant donor-specific transfusion and cyclosporine A administered 24

to 48 hours before one-haplotype-mismatched living related donor kidney transplant. *Ann Surg.* 1992;215(6):618-626.

De Bruin AF, De Witte LP, Stevens F, Diederiks JPM. Sickness impact profile: the state of the art of a generic functional status measure. *Soc Sci Med.* 1992;35(8):1003-1014.

De Francisco ALM, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, et al. Continuous erythropoietin receptor activator (c.e.r.a.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomized, multicentre, multi-dose, phase II study. *Int J Clin Pract.* 2006;60(12):1687-1696.

De Klerk G, Wilmlink JM, Rosengarten PCJ, Vet RJ, Goudsmit R. Serum erythropoietin (ESF) titers in anemia of chronic renal failure. *J Lab Clin Med.* 1982;100:720-734.

De Lurdes Agostinho Cabrita A, Pinho A, Malho A, Morgado E, Faísca M, Carrasquiera H, et al. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5. *Int Urol Nephrol.* 2010;1-6.

De Marchi S, Cecchin E. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin. *Clin Sci (London).* 1991;81:113-121.

De Marchi S, Cecchin E, Villalta D, Sepiacchi G, Santini G, Bartoli E. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. *N Engl J Med.* 1992;326(15):969-974.

De Nicola L, Minutolo R, Conte G. Anaemia management in non-dialysis chronic kidney disease: flexibility of target to target stability? *Nephron Clin Prac.* 2010;114:c236-c241.

De Schoenmakere G, Lameire N, Dhondt A, Van Loo A, Van der Goten J, Duym P, Vanholder R. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.). *Nephrol Dial Transplant.* 1998;13:1770-1775.

Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. *J Renal Nutr.* 2005;15(1):137-141.

Del Vecchio L, Cavalli A, Locatelli F. Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease. *Drugs Today (Barc).* 2008;44(8):577-584.

Del Vecchio L, Cavalli A, Tucci B, Locatelli F. Chronic kidney disease-associated anemia: new remedies. *Curr Opin Investig Drugs.* 2010;11(9):1030-1038.

Der Santos AE, Shalansky KF, Jastrzebski JP. Management of anemia in erythropoietin-resistant hemodialysis patients. *Ann Pharmacother.* 2003;37:1768-1773.

Di Iorio B, Cirillo M, Bellizzi V, Stellato D, De Santo NG. Prevalence and correlates of anemia and uncontrolled anemia in chronic hemodialysis patients-the Campania Dialysis Registry. *Int J Artif Organs.* 2007;30(4):325-333.

DePaul V, Moreland J, Eager T, Clase CM. The effectiveness of aerobic and muscle strength training in patients receiving hemodialysis and EPO: a randomized controlled trial. *Am J Kidney Dis.* 2002;40(6):1219-1229.

Definitions of Quality Measures. <http://www.medicare.gov/Dialysis/Static/Publications.asp?>. Accessed March 30, 2011.

Deicher R, Hörl WH. Vitamin C for hypo-responsiveness to epo: a cure for all? *Am J Kidney Dis.* 2003;42(4):848-849.

Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. *Am J Kidney Dis.* 1989;14(2)(Suppl 1):14-18.

Delwiche F, Segal GM, Eschbach JW, Adamson JW. Hematopoietic inhibitors in chronic renal failure: lack of in vitro specificity. *Kidney Int.* 1986;29:641-648.

Deniston OL, Carpentier-Alting P, Kneisley J, Hawthorne VM, Port FK. Assessment of quality of life in end-stage renal disease. *HSR: Health Serv Res.* 1989;24(4):555-578.

Deniston OL, Luscombe FA, Buesching DP, Richner RE, Spinowitz BS. Effect of long-term epoetin beta therapy on the quality of life of hemodialysis patients. *ASAIO Trans.* 1990;36:M157-M160.

Deray G. Dosing darbepoetin alfa continued. *Am J Kidney Dis.* 2003;41(6):1334-1336.

Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion-related pro-inflammatory responses. *Hematol Oncol Clin N Am.* 2007;21:147-161.

Devins GM, Binik YM, Mandin H, Letourneau PK, Hollomby DJ, Barre PE, Prichard S. The kidney disease questionnaire: a test for measuring patient knowledge about end-stage renal disease. *J Clin Epidemiol.* 1990;43(3):297-307.

Diezhandino MG. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. *Clin Nephrol.* 1996;45(6):420-421.

Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? *Nephrology.* 2006;11:394-399.

Dittrich E, Puttinger H, Schneider B, Hörl WH, Haag-Weber M, Vychytil A. Is absorption of high-dose oral iron sufficient in peritoneal dialysis patients? *Perit Dial Int.* 2000;20:667-673.

Dodd RY, Notari IV EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion.* 2002;42:975-979.

- Dokal I, Pagliuca A, Deenmamode M, Mufti GJ, Lewis SM. Development of polycythaemia vera in a patient with myelofibrosis. *Eur J Haematol* 1989;42:96-98.
- Donnelly SM, Ali M, Churchill DN. Bioavailability of iron in hemodialysis patients treated with erythropoietin: evidence for the inhibitory role of aluminum. *Am J Kidney Dis*. 1990;16(5):447-451.
- Doxiadis II, Persijn GG, Claas FH. The crossmatch policy of the transplantation center influences graft survival in cadaver kidney transplantation. *Clin Transpl*. 2003;143-147.
- Drüeke T, Zins B, Naret C, Casadevall N, Goureau Y, Bererhi L, et al. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. *Adv Nephrol*. 1989;18:187-206.
- Drüeke T. Resistance to recombinant human erythropoietin in hemodialysis patients. *Am J Nephrol*. 1990;10(suppl 2): 34-39.
- Drüeke T. Adynamic bone disease, anaemia, resistance to erythropoietin and iron-aluminum interaction. *Nephrol Dial Transplant*. 1993;Suppl 1:12-16.
- Drüeke T. Hyporesponsiveness to recombinant human erythropoietin. *Nephrol Dial Transplant*. 2001;16(Suppl 7):25-28.
- Drüeke T, Eckardt K. Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. *Nephrol Dial Transplant*. 2002;17(Suppl 5):28-31.
- Drüeke T, Massy ZA. Intravenous iron: how much is too much? *J Am Soc Nephrol*. 2005;16:2833-2835.
- Drüeke T, Locatelli F, Clyne N, Eckardt K, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med*. 2006;355(20):2071-2084.
- Duarte PS, Ciconelli RM, Sesso R. Cultural adaptation and validation of the “kidney disease and quality of life-short form (KDQOL-SF™ 1.3)” in Brazil. *Braz J Med Biol Res*. 2005;38:261-270.
- Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT. Dosing patterns and treatment costs of erythropoietin agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations. *Drugs Aging*. 2006;23(12):969-76.
- Duff DR, Golper TA, Sloan RS, Brier ME, Aronoff GR. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. *Am J Kidney Dis*. 1991;18(1):60-64.
- El-Khatib M, Duncan HJ, Kant KS. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients. *Nephrology*. 2006;11:400-404.
- El-Komy MH, Widness JA, Veng-Pedersen. Pharmacokinetic analysis of C.E.R.A. disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology. *Drug Metab Dispos*. 2011;39(4):603-609.
- Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. *Clin J Am Soc Nephrol*. 2006;1:1205-1210.
- Eckardt K. The CREATE trial—building the evidence. *Nephrol Dial Transplant*. 2001;16[Suppl 2]:16-18.
- Eckardt K. Anaemia in end-stage renal disease: pathophysiological considerations. *Nephrol Dial Transplant*. 2001;16(Suppl 7):2-8.
- Eckardt K. Anaemia of critical illness—implications for understanding and treating rHuEPO resistance. *Nephrol Dial Transplant*. 2002;17(Suppl 5):48-55.
- Eckardt K, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B. Hemoglobin variability does not predict mortality in European hemodialysis patients. *J Am Soc Nephrol*. 2010;21:1765-1775.
- Eckardt K, Drüeke T, Leski M, Kurtz A. Unutilized reserves: the production capacity for erythropoietin appears to be conserved in chronic renal disease. *Contrib Nephrol*. 1991;88:18-34.
- Eckel RH. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. *Proc Nutr Soc*. 2007;66:82-95.
- Eder AF, Chambers LA. Noninfectious complications of blood transfusion. *Arch Pathol Lab Med*. 2007;131:708-718.
- Edgell ET, Coons SJ, Carter WB, Kallich JD, Mapes D, Damush TM, Hays RD. A review of health-related quality-of-life measures used in end-stage renal disease. *Clin Ther*. 1996;18(5):887-1111.
- Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). *Br J Cancer*. 2001;84(Suppl 1):3-10.
- Egrie JC, Browne JK. Development and characterization of darbepoetin alfa. *Oncology (Williston Park)*. 2002;16(10 Suppl 11):13-22.
- Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. *Exp Hematol*. 2003;31:290-299.
- Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, Kaplan B, Halloran PF. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. *Am J Transplant*. 2009;9:2520-2531.
- Eklund SG, Johansson SV, Strandberg O. Anemia in uremia. *Acta Med Scand*. 1971;190:435-443.

Elliott S, Busse L, McCafferty I, Rossi J, Sinclair A, Spahr C, Swift S, Begley CG. Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells. *J Immunol Methods*. 2010;352:126-139.

Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, Rogers N, Ponting I. Control of rHuEPO biological activity: the role of carbohydrate. *Exp Hematol*. 2004;32:1146-1155.

Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. *Adv Chronic Kidney Dis*. 2009;16(2):94-100.

Epogen, Procrit (1990-2010) in Physicians' Desk Reference. San Francisco, CA: Medical Economics.

Epstein JS, Holmberg JA. Progress in monitoring blood safety. *Transfusion*. 2010;50:1408-1412.

Erbes PM, Radtke HW, Schoeppe W, Koch KM. Sustained negative feedback between haematocrit and serum erythropoietin concentration in end-stage renal failure. *Proc Eur Dial Transplant Assoc*. 1978;15:442-448.

Ersler WB, Sheng S, McKelvey J, Artz AS, Denduluri N, Tecson J, et al. Serum erythropoietin and aging: a longitudinal analysis. *J Am Geriatr Soc*. 2005;53:1360-1365.

Erslev AJ, Caro J, Miller O, Silver R. Plasma erythropoietin in health and disease. *Annals of Clinical and Laboratory Science*. 1980;10(3):250-257.

Erslev AJ, Caro J. Erythropoietin titers in anemic, nonuremic patients. *J Lab Clin Med*. 1987;109(4):429-433.

Erslev AJ, Caro J. Erythropoietin titers in response to anemia or hypoxia. *Blood Cells*. 1987;13:207-216.

Erslev AJ, Caro J. Erythropoietin: from mountain top to bedside. *Adv Exp Med Biol*. 1989;271:1-7.

Erturk S. ACE inhibitors and erythropoietin response in hemodialysis patients. *Am J Kidney Dis*. 2000;36(4):1-3.

Erythropoietin (Epogen/Procrit): FDA label; http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s51991bl.pdf.

Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). *Kidney Int*. 1985;28:1-5.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. *N Engl J Med*. 1987;316(2):73-78.

Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. *Ann Intern Med*. 1989;111:992-1000.

Eschbach JW, Kelly MR, Haley R, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. *N Engl J Med*. 1989;321:158-163.

Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. The safety of epoetin-alpha: results of clinical trials in the united states. *Contrib Nephrol*. 1991;88:72-80.

Eschbach JW. Erythropoietin: The promise and the facts. *Kidney Int*. 1994;45(Suppl 44):S70-S76.

Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. *Kidney Int*. 1999;69:S35-S43.

Eschbach JW, Varma A, Stivelman JC. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia? *Nephrol Dial Transplant*. 2002;17(Suppl 5):2-7.

Espósito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. *Eur J Clin Invest*. 2002;32(Suppl 1):42-49.

Essink-Bot ML, Krabbe PFM, van Agt HME, Bonsel GJ. NHP or SIP-a comparative study in renal insufficiency associated anemia. *Qual Life Res*. 1996;5:91-100.

European Renal Association-European Dialysis and Transplant Association. The Guidelines. 1999;14(Suppl 5).

Evans K, Coresh J, Bash LD, Gary-Webb T, Köttgen A, Carson K, et al. Race differences in access to health care and disparities in incident chronic kidney disease in the U.S. *Nephrol Dial Transplant*. 2011;26:899-908.

Evans K, Coresh J, Bash LD, et al. Race differences in access to health care and disparities in incident chronic kidney disease in the U.S. *Nephrol Dial Transplant*. 2011;26:899-908.

Evans K, Rader B, Manninen DL. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. *JAMA*. 1990;263(6):825-830.

Evatt BL, Spivak JL, Levin J. Relationships between thrombopoiesis and erythropoiesis: with studies of the effects of preparations of thrombopoietin and erythropoietin. *Blood*. 1976;48:547-558.

FDA Approves Chagas Disease Screening Test for Blood, Tissue and Organ Donors. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210429.htm>. Accessed May 11, 2011.

FDA Approves First Test to Screen Blood Donors for Chagas Disease. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108802.htm>. Accessed May 11, 2011.

FDA: Aranesp (darbepoetin). BLA: 103951: Complete on-line reviews and approval letter. 2001. (www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080442.htm). Subsequent review history and REMS safety program information. (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#applist) (www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200104.pdf) (Accessed May 11, 2011).

FDA: Epogen, Procrit (erythropoietin). BLA 103234: Summary Basis of Approval. 1989. Reviews from individual disciplines not available. Subsequent review history (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#applist) and REMS safety program information (www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM200105.pdf) (Accessed May 11, 2011).

FDA: Mircera (methoxy polyethylene glycol-epoetin-beta). BLA: 125164: Complete on-line reviews and approval letter. (www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#applist) (Accessed May 11, 2011).

FDA Vaccines, Blood & Biologics: Questions about blood. (Accessed March 2011 at <http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/QuestionsaboutBlood/default.htm>). (Accessed May 11, 2011).

FDA Webinar on Safety of the Blood Supply. February 15, 2011. <http://www.fda.gov/AboutFDA/Transparency/Basics/ucm242826.htm>. (Accessed May 11, 2011).

Farrington K, Udayaraj U, Gilg J, Feehally J. UK Renal Registry 11th Annual Report (December 2008): Chapter 3 ESRD incident rates in 2007 in the UK: national and centre-specific analyses. *Nephron Clin Pract.* 2009;111: Suppl 1:c13-41.

Farrington K, Hodsmann A, Casula A, Ansell D, Feehally J. UK Renal Registry 11th Annual Report (December 2008): Chapter 4 ESRD prevalent rates in 2007 in the UK: national and centre-specific analyses. *Nephron Clin Pract.* 2009;111:Suppl1:c43-68.

Fatalities reported to FDA Following Blood Collection and Transfusion. Annual summary for fiscal year 2009. <http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/UCM205620.pdf>.

Fauchet R, Genetet B, Guegen M, Leguerrier A, Rioux C, Logeais Y. Transfusion therapy and HLA antibody response in patients undergoing open heart surgery. *Transfusion.* 1982;22:320-322.

Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin) a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemias and the stimulation of erythropoietin. *Drugs.* 1989;38(6):863-899.

Fernandez-Reyes MJ, Selgas R, Bajo MA, Jimenez C, Del Paso G, Sanchez M, et al. Increased response to subcutaneous erythropoietin on type I diabetic patients on CAPD: is there a synergistic effect with insulin? *Perit Dial Int.* 1995;15:231-235.

Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece B, Saha SP, et al. 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. *Ann Thorac Surg.* 2011;91:944-982.

Festenstein H, Sachs JA, Paris AMI. Influence of HLA matching and blood-transfusion on outcome of 502 london transplant group renal-graft recipients. *Lancet.* 1976;307(7952):157-161.

Fields R. God help you. You're on dialysis. *The Atlantic.* 2010. <http://www.theatlantic.com/magazine/archive/2010/12/-8220-god-help-you-you-39-re-on-dialysis-8221/8308/>. (Accessed May 11, 2011)

Filiopoulos V, Vlassopoulos D. Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. *Inflamm Allergy Drug Targets.* 2009;8:369-382.

Fine A. Relevance of C-reactive protein levels in peritoneal dialysis patients. *Kidney Int.* 2002;61:615-620.

Finkelstein FO, Story K, Firaneck C, Mendelssohn D, Barre P, Takano T, et al. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. *Clin J Am Soc Nephrol.* 2009;4:33-38.

Fishbane S. Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. *Kidney Int.* 2009;75:358-365.

Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. *Kidney Int.* 2005;68:1337-1343.

Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. *Am J Kidney Dis.* 1995;26(1):41-46.

Fishbane S, Miyawaki N, Sczech LA. Hypothesis: an erythropoietin honeymoon phase exists. *Kidney Int.* 2010;78:646-649.

Fishbane S, Pannier A, Liogier X, Jordan P, Dougherty FC, Reigner B. Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. *J Clin Pharmacol.* 2007;47:1390-1397.

Fisher JW. Control of erythropoietin production. *Proc Soc Exp Biol Med.* 1983;173:289-305.

Fisher JW, Bommer J, Eschbach J, Fried W, Lange RD, Massry S, et al. Statement on the clinical use of recombinant erythropoietin in anemia of end-stage renal disease. *Am J Kidney Dis.* 1989;14(3):163-169.

Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. *Clin Pharmacol Ther.* 1990;47:557-564.

Fletes R, Lazarus M, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. *Am J Kidney Dis.* 2001;37(4):743-749.

- Fluck S, McKane W, Cairns T, Fairchild V, Lawrence A, Lee J, et al. Chloramine-induced haemolysis presenting as erythropoietin resistance. *Nephrol Dial Transplant*. 1999;14:1687-1691.
- Flye MW, Burton K, Mohanakumar T, Brennan D, Keller C, Goss JA, Sicard GA, Anderson CB. Donor-specific transfusions have long-term beneficial effects for human renal allografts. *Transplantation*. 1995;60(12):1395-1401.
- Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. *Clin J Am Soc Nephrol*. 2009;4:726-733.
- Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. *Clin J Am Soc Nephrol*. 2008;3(6):1669-1675.
- Foley RN, Curtis BM, Randell EW, Parfrey PS. Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. *Clin J Am Soc Nephrol*. 2010;5:805-813.
- Foley RN, Parfrey PS, Morgan J, Barré PE, Campbell P, Cartier P, Coyle D, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. *Kidney Int*. 2000;58:1325-1335.
- Frank H, Heusser K, Höffken B, Huber P, Schmieder RE, Schobel HP. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. *Kidney Int*. 2004;66:832-840.
- Freedman MH, Cattran DC, Saunders EF. Anemia of chronic renal failure: inhibition of erythropoiesis by uremic serum. *Nephron*. 1983;35:15-19.
- Frei U, Kwan JTC, Spinowitz BS, the Epoetin Delta 3002 study group. Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study. *BMC Nephrology*. 2009;10:5.
- Frenkel EP, Douglass CC, McCall MS. Hypoerythropoietinemia and anemia. *Arch Intern Med*. 1970;125:1050-1055.
- Frenken LA, van Lier HJ, Gerlag PG, den Hartog M, Koene RA. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. *Br Med J*. 1991;303:288.
- Freudenthaler SM, Schreeb KH, Körner T, Gleiter CH. Angiotensin II increases erythropoietin production in health human volunteers. *Eur J Clin Invest*. 1999;29:816-823.
- Frifelt JJ, Tvedegaard E, Bruun K, Steffensen G, Cinton C, Breddam M, et al. Efficacy of recombinant human erythropoietin administered subcutaneously to capd patients once weekly. *Perit Dial Int*. 1996;16:594-598.
- Frisan E, Pawlikowska P, Pierre-Eugène C, Viallon V, Gibault L, Park S. p-ERK1/2 is a predictive factor of response to erythropoiesis-stimulating agents in low/int-1 myelodysplastic syndromes. *Haematologica*. 2010[Epub ahead of print].
- Fritschka E, Neumayer HH, Seddighi S, Thiede HM, Distler A, Philipp T. Effect of erythropoietin on parameters of sympathetic nervous activity in patients undergoing chronic haemodialysis. *Br J Clin Pharmacol*. 1990;30:135S-138S.
- Fukuda MN, Sasaki H, Lopez L, Fukuda M. Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. *Blood*. 1989;73(1):84-89.
- Fukuhara S, Akizawa T, Morita S, Koshikawa S, KRN321 A08 Study Group. Quality of life improvements in dialysis patients receiving darbepoetin alfa. *Ther Apher Dial*. 2008;12(1):72-77.
- Fukushima Y, Fukuda M, Yoshida K, Yamaguchi A, Nakamoto Y, Miura AK, Harada T, Tsuchida S. Serum erythropoietin levels and inhibitors of erythropoiesis in patients with chronic renal failure. *Tohoku J Exp Med*. 1986;150:1-15.
- Furuland H, Linde T, Ahlmén J, Christensson A, Strömbom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. *Nephrol Dial Transplant*. 2003;18:353-361.
- Furuland H, Linde T, Sandhagen B, Andrén B, Wikström B, Danielson BG. Hemorheological and hemodynamic changes in predialysis patients after normalization of hemoglobin with epoetin- α . *Scand J Urol Nephrol*. 2005;39:399-404.
- Furuland H, Linde T, Wilkström B, Danielson BG. Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. *J Nephrol*. 2005;18:80-85.
- Fusté B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. *Thromb Haemost*. 2002;88:678-685.
- Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism and anemia in renal failure. *Am J Nephrol*. 2000;20:89-96.
- Galvão MM, Peixinho ZF, Mendes NF, Sabbaga E. Stored blood-an effective immunosuppressive method for transplantation of kidneys from unrelated donors. An 11-year follow-up. *Braz J Med Biol Res*. 1997;30:727-734.
- Gandra SR, Finkelstein FO, Bennett AV, Lewis EF, Brazg T, Martin ML. Impact of erythropoiesis-stimulating agents on energy and physical function in nondialysis CKD patients with anemia: a systematic review. *Am J Kidney Dis*. 2010;55(3):519-534.
- Galstaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. *Nephrol Dial Transplant*. 1995;10(Suppl 6):44-47.
- Gaughan WJ, Liss KA, Dunn SR, Mangold A, Buhsmer JP, Michael B, Burke JF. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. *Am J Kidney Dis*. 1997;30(4):495-500.

- Geary DF, Keating LE, Vigneux A, Stephens D, Hébert D, Harvey EA. Darbepoetin alfa (Aranesp™) in children with chronic renal failure. *Kidney Int.* 2005;68:1759-1765.
- Gebel HM, Halloran PF. Making sense of desensitization. *Am J Transplant.* 2010;10:443-444.
- Gee K, Guzzo C, Mat NFC, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. *Inflamm Allergy Drug Targets.* 2009;8:40-52.
- Geisser P, Baer M, Schaub E. Structure/Histotoxicity relationship of parenteral iron preparations. *Arzneimittel for Schung.* 1992;42(12):1439-1452.
- Geisser P, Müeller A. Iron pharmacokinetics after administration of ferric-hydroxide-polymaltose complex in rats. *Arzneimittel for Schung.* 1984;34(11):1560-1569.
- Ghaboura N, Tamareille S, Dulcluzeau P, Grimaud L, Loufrani L, Croué A, et al. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3 β signaling. *Basic Res Cardiol.* 2011;106:147-162.
- Ghezzi P, Bernaudin M, Bianchi R, Blomgren, et al. Erythropoietin: not just about erythropoiesis. *Lancet.* 2010;375:2142.
- Glasscock R. *Current Therapy in Nephrology and Hypertension.* Toronto: B.C. Decker Inc. 1987; v2.
- Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. *J Nephrol.* 2000;13:444-449.
- Gilson BS, Gilson JS, Bergner M, Bobbitt RA, Kressel S, Pollard WE, Vesselago M. The sickness impact profile: development of an outcome measure of health care. *Am J Public Health.* 1975;65(12):1304-1310.
- Gilbretson DT, Guo H, Arneson TJ, et al. Transfusion-related complications in kidney patients. *Am Soc Nephrol.* 2010.
- Gimenez LF, Watson AJ, Spivak JL. Serum Immunoreactive erythropoietin in patients with end stage renal disease. *Prog Clin Biol Res.* 1990;352:493-504.
- Goch J, Birgegård G, Danielson BG, Wikström B. Treatment of erythropoietin-resistant anaemia with desferrioxamine in patients on haemofiltration. *Eur J Haematol.* 1995;55:73-77.
- Goh B, Ong L, Sivanandam S, Lim T, Morad Z. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. *Nephrology.* 2007;12:431-436.
- Goicoechea M, Caramelo C, Rodriguez P, Verde E, Gruss E, Albalate M, et al. Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis. *Nephrol Dial Transplant.* 2001;16:2188-2193.
- Goicoechea M, Martin J, De Sequera P, Quiroga JA, Ortiz A, Carreño V, Caramelo C. Role of cytokines in the response to erythropoietin in hemodialysis patients. *Kidney Int.* 1998;54:1337-1343.
- Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrábano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. *Nephron.* 1998;78:23-27.
- Gomez-Alamillo C, Fernández-Fresnedo G, Ortega F, Campistol JM, Gentil MA, Arias M. Erythropoietin resistance as surrogate marker of graft and patient survival in renal transplantation: 3-year prospective multicenter study. *Transplant Proc.* 2010;42:2935-2937.
- Gonzalez F. Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Undergoing Hemodialysis and Receiving Epoetin. *N Eng J Med.* 1988;339:2023-2034
- Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, et al. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. *J Am Soc Nephrol.* 2011;22:358-365.
- Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. *Blood.* 2000;96(3):823-833.
- Gordon MY, Riley GP, Greaves MF. Plastic-adherent progenitor cells in human bone marrow. *Exp Hematol.* 1987;15:772-778.
- Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. *Kidney Int.* 2004;66(2):753-760.
- Graf H. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. *Nephron.* 1992;61:399-403.
- Granolleras C, Leskoff W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. *Clin Nephrol.* 1991;36(6):294-298.
- Greenwood RN, Ronco C, Gastaldon F, Brendolan A, Homel P, Usvyat L, et al. Erythropoietin dose variation in different facilities in different countries and its relationship to drug resistance. *Kidney Int.* 2003;64(Suppl 87):S78-S86.
- Grützmacher P, Radtke HW, Fassbinder W, Koch K-M, Schoeppe. Effect of secondary hyperparathyroidism on the anaemia of end-stage renal failure: in vivo and in vitro studies. *Proc Eur Dial Transplant Assoc.* 1983;20:739-745.
- Grützmacher P, Bergmann M, Weinreich T, Nattermann U, Reimers E, Pollok M. Beneficial and adverse effects of correction of anaemia by recombinant human erythropoietin in patients on maintenance haemodialysis. *Contrib Nephrol.* 1988;66:104-113.
- Grützmacher P, Scheuermann E, Löw I, Bergmann M, Rauber K, Baum R. Correction of renal anaemia by recombinant human erythropoietin: effects on

myocardial function. *Contrib Nephrol.* 1988;66:176-184.

Guidi GC, Lechi Santonastaso C. Advancements in anemias related to chronic conditions. *Clin Chem Lab Med.* 2010;48(9):1217-1226.

Gurney CW, Goldwasser E, Pan C. Studies on erythropoiesis. VI. Erythropoietin in human plasma. *J Lab Clin Med.* 1957;50(4):534-542.

Guthrie M, Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW. Effects of erythropoietin on strength and functional status of patients on hemodialysis. *Clin Nephrol.* 1993;39(2):97-102.

Haag-Weber M, Vetter A, Thyroff-Friesinger U. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. *Clin Nephrol.* 2009;72(5):380-390.

Hajeer AH. Panel reactive antibody test (PRA) in renal transplantation. *Saudi J Kidney Dis Transplant.* 2006;17(1):1-4.

Hajjar LA, Vincent J, Galas FR, Nakamura RE, Silva CMP, Santos MH, et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. *JAMA.* 2010;304(14):1559-1567.

Hall YN, Choi AI, Xu P, O'Hare AM, Chertow GM. Racial ethnic differences in rates and determinants of deceased donor kidney transplantation. *J Am Soc Nephrol.* 2011;22:743-751.

Halloran PF. T cell mediated rejection of kidney transplants: a personal viewpoint. *Am J Transplant.* 2010;10:1126-1134.

Hampel H, Riedel E, Wendel G, Scigalla P. Red blood cell density distribution in uremic patients on acetate and bicarbonate hemodialysis. *Blood Purif.* 1990;8:260-267.

Handelman GJ. Newer strategies for anemia prevention in hemodialysis. *Int J Artif Organs.* 2007;30(11):1014-1019.

Handelman GJ, Levin NW. Red cell survival: relevance and mechanism involved. *J Ren Nutr.* 2010;20(55):S84-S88.

Hansen RA, Chin H, Blalock S, Joy MS. Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. *Res Social Adm Pharm.* 2009;5(2):143-153.

Hardy S, Lee S, Terasaki PI. Chapter 24: Sensitization 2001. *Clin Transpl.* 2001:271-278.

Harmon WE, Alexander SR, Tejani A, Stablein D. The effect of donor age on graft survival in pediatric cadaver renal transplant recipients-a report of the north American pediatric renal transplant cooperative study. *Transplantation.* 1992;54(2):232-237.

Harris AM, Atterbury CLJ, Chaffe B, Elliott C, Hawkins T, Hennem SJ, et al. Guideline on the administration of blood components. *British Committee for Standards in Haematology.* 2002;1-59.

Harris DCH, Chapman JR, Stewart JH, Lawrence S, Roger SD. Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis. *Aust NZ J Med.* 1991;21:693-700.

Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. *Kidney Int.* 2001;60:1910-1916.

Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. *Br J Pharmacol.* 1998;46:11-19.

Hayat A, Haria D, Salifu M. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. *Patient Prefer Adherence.* 2008;2:195-200.

Hays RD, Kallich JD, Mapes DL, Coons SJ, Carter WB. Development of the kidney disease quality of life (KDQOL™) instrument. *Qual Life Res.* 1994;3:329-338.

Health Resource and Services Administration. The 2009 OPTN/SRTR Annual Report: Transplant Data 1999-2008 (Accessed March 2011 at http://www.ustransplant.org/annual_reports/current/).

Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. *N Engl J Med.* 1999;340:409-417.

Hébert PC, Van der Linden P, Biro G, Hu LQ. Physiologic aspects of anemia. *Crit Care Clin.* 2004;20:187-212.

Heim MU. Guidelines of the German Medical Association for therapy with blood components and plasma derivatives--an introduction. Evidence-based recommendations for the risk-benefit analysis in hemotherapy. *Anesthesiol IntensiveMed Notfallmed Schmerzther.* 2009; 44(3) 186-197.

Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA.* 2010;303(5):423-429.

Hébert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular disease? *Crit Care Med.* 2001;29(2):227-234.

Herrera J, Nava M, Biol L, Romero F, Biol L, Rodríguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. *Am J Kidney Dis.* 2001;37(4):750-757.

Hiesse C, Busson M, Buisson C, Farahmand H, Bierling P, Benbunan M, et al. Multicenter trial of one HLA-DR-matched or mismatched blood transfusion prior

to cadaveric renal transplantation. *Kidney Int.* 2001;60:341-349.

Hillis AN, MacLeod AM, Al-Muzairai IA, Innes A, Stewart KN, Power DA, et al. Antidiotypic activity and sensitization after donor-specific transfusion (DST) given with and without cyclosporine (CsA). *Transplant Proc.* 1989;21(1):1820-1821

Hiramatsu M, Kubota M, Iwasaki M, Akizawa T, Koshikawa S, KRN321 A09 Study Group. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients. *Ther Apher Dial.* 2008;12(1):19-27.

Hodsman A, Lamb EJ, Steenkamp R, Warwick G. Biochemistry profile of patients receiving dialysis in the UK in 2007: national and centre-specific analyses (Ch 10). 2008:185-222.

Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. *J Am Soc Nephrol.* 1998;9:869-876.

Holmberg JA. Progress in monitoring blood safety. *Transfusion.* 2010;50:1408-1412.

Holycross BJ, Radin MJ. Cytokines in heart failure: potential interactions with angiotensin II and leptin. *Mol Interv.* 2002;2(7):424-427.

Hon G, Vaziri ND, Kaupke CJ, Tehranzadeh A, Barton C. Lack of fast-acting effect of erythropoietin on arterial blood pressure and endothelin level. *Artif Organs.* 1995;19(2):188-191.

Horemans HL, Nollet F, Beelen A, Lankhorst GJ. A comparison of 4 questionnaires to measure fatigue in postpoliomyelitis syndrome. *Arch Phys Med Rehabil.* 2004;85:392-398.

Hörl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. *Acta Haematol.* 1992;87(suppl 1):16-19.

Hörl WH. Non-erythropoietin-based anemia management in chronic kidney disease. *Nephrol Dial Transplant.* 2002;17(Suppl 11):35-38.

Howman R, Kulkarni H. Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetin. *Nephrol Dial Transplant.* 2007;22:1462-1464.

Hsu C, McCullough CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. *J Am Soc Nephrol.* 2002;13:504-510.

Hudson JQ, Comstock TJ. Considerations for optimal iron use for anemia due to chronic kidney disease. *Clin Ther.* 2001;23(10):1637-1671.

Hughes RT, Cotes PM, Oliver DO, Pippard MJ, Royston P, Stevens JM, Strong CA, Tam RC, Winearls CG. Correction of the anaemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on haemodialysis and CAPD. *Contrib Nephrol.* 1989;76(1):122-130.

Hughes RT, Smith T, Hesp R, Hulme B, Dukes DC, Bending MB, Pearson J, et al. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores. *Br J Haematol.* 1992;82:445-454.

Hung S, Tung T, Yang C, Tarng D. High-calorie supplementation increases serum leptin levels and improves response to rHuEPO in long-term hemodialysis patients. *Am J Kidney Dis.* 2005;45(6):1073-1083.

Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived health status: a validation study. *J Epidemiol Community Health.* 1980;34:281-286.

Hunt SM, McKenna SP, McEwen J, Williams J, Papp E. The Nottingham health profile: subjective health status and medical consultations. *Soc Sci Med.* 1981;15A:221-229.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O. Different involvement of the megakaryocytic lineage by the JAK2(V617F) mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. *Ann Hematol.* 2007;86:245-253.

Ibrahim HN, Skeans MA, Li Q, Ishani A, Snyder JJ. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. *Clin Transplant.* 2011.; Jan 28 [E pub ahead of print]

Ibrahim HN, Ishani A, Foley RN, Guo H, Liu J, Collins AJ. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. *Am J Kidney Dis.* 2008;52(6):115-1121. Epub 2008 Sept 27.

Ibrahim HN, Ishani A, Guo H, Gilbertson DT. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. *Nephrol Dial Transplant.* 2009;24(10):3138-3143. Epub 2009 May 18.

Icardi A, Sacco P, Salvatore F, Romano U. Long-term intravenous epoetin- α /darbepoetin- α ratio in iron-replete hemodialysis patients. *J Nephrol.* 2007;20:73-79.

Ifudu O, Chan E, Paul H, Mayers JD, Cohen LS, Brezsnayk WF, et al. Anemia severity and missed dialysis treatments in erythropoietin-treated hemodialysis patients. *ASAIO J.* 1996;42:146-149.

Imamura K. Effects of intravenous administration of iron preparations on the metabolism of phosphorus. *Acta Med.* 1984;75(6):316-326.

Inglehart JK. Bundled payment for ESRD-including ESAs in Medicare's dialysis package. *N Engl J Med.* 2011;364(7):593-595.

Ingle E, Tilbrook PA, Klinken SP. New insights into the regulation of erythroid cells. *IUBMB Life.* 2004;56:177-184.

- Isbister JP, Shander A, Spahn DR, Erhard J, Farmer SL, Hofmann A. Adverse blood transfusion outcomes: establishing causation. *Trans Med Rev.* 2011;25(2):89-101.
- Ishani A, Guo H, Arneson TJ, Gilbertson DT, Mau L. Possible effects of the new medicare reimbursement policy on African Americans with ESRD. *J Am Soc Nephrol.* 2009;20:1607-1613.
- Ishimura E, Nishizawa Y, Okuno S, Matsumoto N, Emoto M, Inaba M, et al. Diabetes mellitus increases the severity of anemia in non-dialyzed patients with renal failure. *J Nephrol.* 1998;11(2):82-86.
- Islam S, Rahman H, Rashid HU. Effect rHuEpo on predialysis CRF patients: study of 45 cases. *Bangladesh Med Res Counc Bull.* 2005;31(2):83-87.
- Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. *Cancer.* 2008;112:1089-1095.
- Jacobs C, Frei D, Perkins AC. Results of the European survey on anaemia management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. *Nephrol Dial Transplant.* 2005;20[Suppl 3]:iii3-iii24.
- Jacobs A, Janowska-Wieczorek A, Caro J, Bowen DT, Lewis T. Circulating erythropoietin in patients with myelodysplastic syndromes. *Br J Haematol.* 1989;73:36-39.
- Jagsch R, Pils K. Which instrument is more suitable to assess health-related quality of life: Nottingham Health Profile or Short-Form-36? *Wien Med Wochenschr.* 2006;156:149-157.
- Janssen MJA, van der Kuy A, ter Wee PM, van Boven WPL. Calcium acetate versus calcium carbonate and erythropoietin dosages in haemodialysis patients. *Nephrol Dial Transplant.* 1995;10:2321-2324.
- Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. *Am J Hematol.* 2010;85:771-780.
- Jenkinson C. Why are we weighting? A critical examination of the use of item weights in a health status measure. *Soc Sci Med.* 1991;32(12):1413-1416.
- Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. *Eur J Clin Pharmacol.* 1996;50:171-177.
- Jensen GV, Nielsen B. Adverse effects of subcutaneous administration of erythropoietin solution versus lyophilisate in patients receiving hemodialysis. *Ugeskr Laeger.* 1994;156(2):183-184.
- Jeong K, Lee T, Ihm C, Lee S, Moon J. Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis. *Exp Mol Med.* 2008;40(2):161-166.
- The Johns Hopkins Comprehensive Transplant Center Incompatible Kidney Transplant Programs. http://www.hopkinsmedicine.org/bin/w/h/InKTP_brochure.pdf. (Accessed 12/15/2010)
- Johansen KL, Finkelstein FO, Revicki DA, Gitlin M, Evans C, Mayne TJ. Systematic review and meta-analysis of exercise tolerance with physical functioning in dialysis patients treated with erythropoiesis-stimulating agents. *Am J Kidney Dis.* 2010;55(3):535-548.
- Johnson DL, Farrell FX, Barbone FP, McMahon FJ, Tullai J, Hoey K, et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. *Biochemistry.* 1998;37:3699-3710.
- Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. *Blood.* 1989;74(1):130-138.
- Jones MC, Stewart KN, Propper DJ, Catto GR, Power DA. The effect of cyclosporine administered during a third-party blood transfusion protocol on humoral immune responses. *Nephrol Dial Transplant.* 1991;6:125-130.
- Kainz A, Mayer B, Kramar R, Oberbauer. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. *Nephrol Dial Transplant.* 2010;1-6.
- Kakumitsu H, Kamezaki K, Shimoda K, Karube K, Haro T, Numata A, et al. Transgenic mice overexpressing murine thrombopoietin develop myelofibrosis and osteosclerosis. *Leuk Res.* 2005;29:761-769.
- Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. *Am J Kidney Dis.* 2009;53(5):823-834.
- Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. *Adv Ren Replace Ther.* 2003;10(3):155-169.
- Kallich JD, Hays RD. The benefits and pitfalls of Health Serv Res funded by proprietary firms. *Qual Life Res.* 1994;3:231-233.
- Kallich JD, Hays RD, Mapes DL, Coons SJ, Carter WB. The RAND kidney disease and quality of life instrument. *Nephrol News Issues.* 1995;9(9):29,36.
- Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. *Nephron.* 1992;61:393-398.
- Kampf D, Kahl A, Passlick J, Pustelnik A, Eckardt K, Ehmer B, et al. Single-dose kinetics of recombinant human erythropoietin after intravenous, subcutaneous and intraperitoneal administration. *Contrib Nephrol.* 1989;76:106-111.
- Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, et al. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood

pressure. *Adv Ther.* 2007;24(2):346-352.

Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent-resistance anemia in dialysis patients: review of causes and management. *Blood Purif.* 2010;29:1-12.

Kang D, Yoon K, Han D. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients. *Nephrol Dial Transplant.* 1998;13:2877-2883.

Kang JY, Ho K, Yeoh K, Guan R, Wee A, Lee E, et al. Peptic ulcer and gastritis in uraemia, with particular reference to the effect of helicobacter pylori infection. *J Gastroenterol Hepatol.* 1999;14:771-778.

Kang JY. The gastrointestinal tract in uremia. *Dig Dis Sci.* 1993;38(2):257-268.

Kang JY, Wee A, Choong HI, Wu AYT. Erosive prepyloric changes in patients with end-stage renal failure undergoing maintenance dialysis treatment. *Scand J Gastroenterol.* 1990;25:746-750.

Karpinski M, Pochinco D, Dembinski I, Laidlaw W, Zacharias J, Nickerson P. Leukocyte reduction of red blood cell transfusion does not decrease allosensitization rates in potential kidney transplant candidates. *J Am Soc Nephrol.* 2004;15:818-824.

Kato A, Odamaki M, Takita T, Furuhashi M, Maruyama Y, Hishida A. High blood soluble receptor p80 for tumour necrosis factor α is associated with erythropoietin resistance in haemodialysis patients. *Nephrol Dial Transplant.* 2001;16:1838-1844.

Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. *N Engl J Med.* 1998;339:578-583.

Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, Vaamonde CA. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. *Kidney Int.* 2001;60:300-308.

Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. *J Am Soc Nephrol.* 1993;3(10):1672-1679.

Kawakami K, Takama H, Nakashima D, Tanaka H, Uchida E, Akizawa T. Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. *Eur J Clin Pharmacol.* 2009;65(2):169-178.

Kaysen GA. Inflammation nutritional state and outcome in end stage renal disease. *Miner Electrolyte Metab.* 1999;25:242-250.

Kaysen GA, Müller HG, Ding J, Chertow GM. Challenging the validity of the EPO index. *Am J Kidney Dis.* 2006;47(1):157-166.

Kaysen GA. Biochemistry and biomarkers of inflamed patients: why look, what to access. *Clin J Am Soc Nephrol.* 2009;4:S56-S63.

Keane WF, Lyle PA. Recent advances in management of Type 2 diabetes and nephropathy: lessons from the RENAAL study. *Am J Kidney Dis.* 2003;41(3)(Suppl 1):S22-S25.

Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. *Kidney Int.* 2008;74(6):695-697.

Kelly S, Jessop EG. A comparison of measures of disability and health status in people with physical disabilities undergoing vocational rehabilitation. *J Public Health med.* 1996;18(2):169-174.

Kendall RG, Jeffries R, Cavill I, Norfolk DR. Relationship between endogenous erythropoietin levels, reticulocyte count, and reticulocyte RNA distribution. *Ann N Y Acad Sci.* 1994;718:353-355.

Kennedy JA, Barabé F, Patterson BJ, Bayani J, Squire JA, Barber DL, Dick JE. Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo. *Proc Natl Acad Sci USA.* 2006;103(45):16930-16935.

Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. *Contrib Nephrol.* 1991;88:81-86;discussion 87-89.

Keown PA, Churchill DN, Poulin-Costello M, Lei L, Gantotti S, Agodoa I, et al. Dialysis patients treated with epoetin alfa show improved anemia symptoms: a new analysis of the Canadian erythropoietin study group trial. *Hemodial Int.* 2010;14:168-173.

Kessler M, Martínez-Castelao A, Siamopoulos KC, Villa G, Spinowitz B, Dougherty F, Beyer U. C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: the ARCTOS extension study. *Hemodial Int.* 2010;14:233-239.

Keven K, Kutlay S, Nergizoglu G, Ertürk S. Randomized, crossover study of the effect of vitamin c on EPO response in hemodialysis patients. *Am J Kidney Dis.* 2003;41:1233-1239.

Khankin EV, Mutter WP, Tamez H, Yuan H, Karumanchi SA, Thadhani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. *PLoS ONE.* 2010;5(2):1-9.

Khedr E, El-Sharkawy M, Abdulwahab S, Nor Eldin E, Ali M, Youssif A, Ahmed B. Effect of recombinant human erythropoietin on insulin resistance in hemodialysis patients. *Hemodialysis International.* 2009;13:340-346.

Kilpatrick RD, Critchlow CW, Fishbane S, Besarab A, Stehman-Breen C, Krishnan M, Bradbury BD. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. *Clin J Am Soc Nephrol.* 2008;3(4):1077-1083.

- Kim CD, Park SH, Kim DJ, Park JW, Do JY, Shin SK, et al. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients. *Nephrology*. 2009;14(5):482-487.
- Kim JK, Park BS, Park MJ, Choi W, Ma SK, Nah MY, et al. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis. *Korean J Intern Med*. 2001;16(2):110-117.
- Kirkley SA. Proposed mechanisms of transfusion-induced immunomodulation. *Clin Diagn Lab Immunol*. 1999; (6)5:652-657.
- Kirschner KM, Baltensperger K. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells. *Mol Cancer Res*. 2003;1(1)3:970-980.
- Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis. *Nephron Clin Pract*. 2011;117:c373-c378.
- Klarenback S, Heidenheim AP, Leitch R, Lindsay RM, the Daily/Nocturnal Dialysis Study Group. Reduced requirement for erythropoietin with Quotidian hemodialysis therapy. *ASAIO J*. 2002;48:57-61.
- Klein HG. How safe is blood, really? *Biologicals*. 2010;38:100-104.
- Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. *Lancet*. 2007;370:415-426.
- Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. *Am J Kidney Dis*. 1989;14(6):486-495.
- Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, et al. Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered ever 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. *Am J Kidney Dis*. 2007;50(6):989-1000.
- Klinkmann H, Wiczorek, Scigalla P. Adverse effects of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study. *Artif Organs*. 1993;17(4):219-225.
- Knauf F, Aronson PS. ESRD as a window into America's cost crisis in health care. *J Am Soc Nephrol*. 2009;20:2093-2097.
- Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P. The use of epoetin beta in anemic predialysis patients with chronic renal failure. *Clin Nephrol*. 1995;44(3):201-208.
- Koch KM, Radtke HW. Role of erythropoietin deficiency in the pathogen of renal anemia. *Klin Wochenschr*. 1979;57(19):1031-1036.
- Kong JM, Jeong JH, Kang JK, Seong IG, Kim BC. Donor-specific transfusion in living related and unrelated donor kidney transplantation: minimal sensitization and excellent graft outcome. *Transplant Proc*. 1995;27(1):1036-1037.
- Kontos PC, Miller K, Brooks D, Jassal SV, Spanjevic L, Devins GM, et al. Factors influencing exercise participation by older adults requiring chronic hemodialysis: a qualitative study. *Int Urol Nephrol*. 2007;39:1303-1311.
- Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM. Anemia and outcomes in patients with heart failure. *Arch Intern Med*. 2005;165:2237-2244.
- Kotaki M, Uday K, Henriquez M, Blum S, Dave M. Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. *Clin Nephrol*. 1997;48(1):63-64.
- Kotanko P, Thijssen S, Levin NW. Association between erythropoietin responsiveness and body composition in dialysis patients. *Blood Purif*. 2008;26:82-89.
- Kouidi E, Albani M, Natsis K, Megalopoulos A, Gigis P, Guiba-Tziampiri O. The effects of exercise training on muscle atrophy in haemodialysis patients. *Nephrol Dial Transplant*. 1998;13:685-699.
- Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of erythropoietin-producing cells in kidneys of mice in situ hybridization: correlation with hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. *Blood*. 1989;74(2):645-651.
- Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM. Erythropoietin response to critical illness. *Crit Care Med*. 1994;22:821-826.
- Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemia. *Blood*. 1997;90(5):2057-2061.
- Kraus ES, Parekh RS, Oberai P, Lepley D, Segev DL, Bagnasco S, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. *Am J Transplant*. 2009;9:1826-1834.
- Krishnan G, Thacker L, Angstadt JD, Capelli JP. Multicenter analysis of renal allograft survival in lupus patients. *Transplant Proc*. 1991;23(2):1755-1756.
- Krivoshiev S, Todorov VV, Manitus J, Czekalski S, Scigalla P, Koytchev R. Comparison on the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. *Curr Med Res Opin*. 2008;24(5):1407-1415.
- Krivoshiev S, Wizemann V, Czekalski S, Schiller A, Plješa S, Wolf-Pflugmann M, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. *Adv Ther*. 2010;27(2):105-117.
- Krumwieg D, Arnold I, Seiler FR. Comparison of relevant biological assays for the determination of biologically active erythropoietin. *Dev Biol Stand*. 1988;69:15-22.

Kudasheva DS, Lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. *J Inorg Biochem.* 2004;98:1757-1769.

Kühn K, Nonnast-Daniel B, Grützmacher P, Grüner J, Pfaffl W, Baldamus CA, Scigalla P. Analysis of initial resistance of erythropoiesis to treatment with recombinant human erythropoietin. *Contrib Nephrol.* 1988;66:94-103.

Kulzer P, Schaefer RM, Krahn R, Schaefer L, Heidland A. Effectiveness and safety of recombinant human erythropoietin (r-HuEPO) in the treatment of anemia of chronic renal failure in non dialysis patients. European Multicentre Study Group. *Int J Artif Organs.* 1994;17(4):195-202.

Kuriyama S, Tomonari H, Yoshida T, Kawaguchi Y, Sakai O. Reversal of anemia of erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. *Nephron.* 1997;77:176-185.

Le Meur Y, Lorgeot V, Comte L, Szelag J, Aldigier J, Leroux-Robert C, Praloran V. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. *Am J Kidney Dis.* 2001;38(93):510-517.

Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. *Am J Kidney Dis.* 1995;26(5):757-764.

Lacout C, Pisani DF, Tulliez M, Gachelin FM, Vainchecker W, Villeval J. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. *Blood.* 2006;108(5):1652-1660.

Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. *Am J Kidney Dis.* 2003;41(1):111-124.

Lai KN, Lui SF, Leung JCK, Law E, Nicholls MG. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. *Nephron.* 1991;57:394-400.

Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. *Oncogene.* 2005;24:4442-4449.

Lamas JM, Alonso M, Sastre F, García-Trío G, Saavedra J, Palomares L. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements-a randomized study. *Nephrol Dial Transplant.* 2006;21:2851-2858.

Lamperi S, Carozzi S, Icardi A. Improvement of erythropoietin in uremic patients on CAPD. *Int J Artif Organs.* 1983;6(4):191-194.

Lamping DL, Rowe P, Black N, Lessof L. Development and validation of an audit instrument: the prostate outcomes questionnaire. *Br J Urol.* 1998;82:49-62.

Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. *Am J Nephrol.* 2005;25:400-410.

Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin. *Semin Nephrol.* 1990;10(2):11-19.

Laupacis A. A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. *Transplant Proc.* 1991;23(2):1825-1826.

Laupacis A, Muirhead N, Keown P, Wong C. A disease-specific questionnaire for assessing quality of life in patients on hemodialysis. *Nephron.* 1992;60:302-306.

Laupacis A, Wong C, Churchill D, The Canadian Erythropoietin Study Group. The use of generic and specific quality-of-life measures in hemodialysis patients treated with erythropoietin. *Control Clin Trials.* 1991;12:168S-179S.

Laville M. New strategies in anaemia management: ACORD. *Acta Diabetol.* 2004;41:S18-S22.

Lavoratti GC, Seracini D, Pela I, Materassi M, Vichi GF, Di Lollo S, Bartolozzi G. Resistance to recombinant human erythropoietin therapy in a child with renal failure due to primary hyperoxaluria type 1. *Nephrol Dial Transplant.* 1994;9:1645-1648.

Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Transfusion burden among patients with chronic kidney disease and anemia. *Clin J Am Soc Nephrol.* 2010;5:667-672.

Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, et al. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. *Nephrol Dial Transplant.* 2010;25:2237-2244.

Lazarus HM, Goodnough LT, Goldwasser E, Long G, Arnold JL, Strohl KP. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting. *Bone Marrow Transplantation.* 1992;10:71-75.

Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. *Kidney Int.* 2009;75:15-24.

Lee DB, David BN. Interrelationship between erythropoietin and erythropoiesis: insights from renal transplantation. *Am J Kidney Dis.* 1991;4(1):54-56.

Lee GS. Medical problems in dialysis patients awaiting renal transplantation. *Ann Acad Med (Singapore).* 1991;20(4):519-523.

Lee Y, Koo J, Kim J, Park I, Joo M, Yoon J, et al. Effect of route of EPO administration on hemodialysis arteriovenous vascular access failure: a randomized controlled trial. *Am J Kidney Dis.* 2009;53(5):815-822.

Lee YK, Kim SG, Seo JW, Oh JE, Yoon JW, Koo JR, et al. A comparison between once-weekly and twice-or-thrice weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study. *Nephrol Dial Transplant.* 2008;23(10):3240-3246.

- Leikis MJ, Kent AB, Becker GJ, McMahon LP. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients. *Nephrology*. 2004;9:153-160.
- Leikis M, McKenna MJ, Petersen AC, Kent AB, Murphy KT, Leppik A, et al. Exercise performance falls over time in patients with chronic kidney disease despite maintenance of hemoglobin concentration. *Clin J Am Soc Nephrol*. 2006;1:488-495.
- Le Meur Y, Lorgeot V, Compte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. *Am J Kidney Dis*. 2001;38(3):510-517
- Levey AS, Stevens LA, Coresh J. Conceptual model of CKD: applications and implications. *Am J Kidney Dis*. 2009;53(3)(Suppl 3):S4-S16.
- Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, et al. Canadian randomized trial of hemoglobin maintenance to prevent of delay left ventricular mass growth in patients with CKD. *Am J Kidney Dis*. 2005;46(5):799-811.
- Levin A. Understanding recent haemoglobin trials in ckd: methods and lesson learned from CREATE and CHOIR. *Nephrol Dial Transplant*. 2007;22:309-312.
- Levin A. Management of anemia with intravenous methoxy polyethylene glycol-epoetin beta in patients on dialysis. *Nat Clin Pract Nephrol*. 2008;4(4):186.
- Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. *Am J Kidney Dis*. 2008;52(4):661-667.
- Levin A, Hemmelgarn B, Culeton B, Tobe S, McFarlane P, Ruzicka M, et al. Guidelines for the management of chronic kidney disease. *CMAJ*. 2008;179(11):1154-1162.
- Levin A. Predicting outcomes in CKD: the importance of perspectives, populations and practices. *Nephrol Dial Transplant*. 2009;24:1724-1726.
- Levin A, Beaulieu. TREAT: implications for guideline updates and clinical care. *Am J Kidney Dis*. 2010;55(6):984-987.
- Levin NW, Fishbane S, Canedo FV, Zeig S, Nassar GM, Moran JE. Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomized non-inferiority trial (MAXIMA). *Lancet*. 2007;370:1415-1421.
- Levin RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJP, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. *Cancer Cell*. 2005;7:387-397.
- Lewis NP, Macdougall IC, Willis N, Coles GA, Williams JD, Henderson AH. Effects of the correction of renal anaemia by erythropoietin on physiological changes during exercise. *Eur J Clin Invest*. 1993;23:423-427.
- Li W, Chu T, Huang J, Wu M, Wu K. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis. *J Formos Med Assoc*. 2008;107(11):843-850.
- Li X, Anderson J, Hutzler D, Roodman GD. Hemin-induced erythroid differentiation changes the sensitivity of K562 cells to tumor necrosis factor- α . *Exp Hematol*. 1989;17:1059-1062.
- Liang K, Esteva FJ, Albarracín C, Stemke-Hale K, Lu Y, Bianchini G, et al. Recombinant human erythropoietin antagonizes Trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. *Cancer Cell*. 2010;18:423-435.
- Lietz K, Lao M, Paczek L, Górski A, Gaciong Z. The impact of pretransplant erythropoietin therapy on late outcomes on renal transplantation. *Ann Transplant*. 2003;8(2):17-25.
- Light JA, Metz S, Oddenino K, Simonis T, Strong DM, Reinmuth B, Kumar J, Biggers JA. Fresh versus stored blood in donor specific transfusion. *Transplant Proc*. 1982;14(2):296-301.
- Lillevang ST, Pedersen FB. Quality of life of hemodialysis patients before and after erythropoietin therapy. A double-blind, randomized, placebo controlled study (Danish). *Ugeskr Laeger*. 1990;152(41):2999-3002.
- Lim VS, DeGowin RL, Zavala D, Kirchner PT, Abels R, Perry P, Fangman J. Recombinant human erythropoietin treatment in pre-dialysis patients. *Ann Intern Med*. 1989;110:108-114.
- Lim VS, Kirchner PT, Fangman J, Richmond J, DeGowin RL. The safety and efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. *Am J Kidney Dis*. 1989; 14(6):496-506.
- Lim CS, Vaziri ND. The effects of iron dextran on the oxidate stress in cardiovascular tissues of rats with chronic renal failure. *Kidney Int*. 2004; 65:1802-1809. A
- Lim CS, Vaziri ND. Iron and oxidation stress in renal insufficiency. *Am J Nephrol*. 2004;24:569-575. B
- Lin C, Huang C, Yu C, Wu C, Chang C, Hsu H, et al. Improved iron utilization and reduced erythropoietin resistance by on-line hemodiafiltration. *Blood Purif*. 2002;20:349-356.
- Lindeboom R, Holman R, Mmath, Dijkgraaf MGW, Sprangers MAG, Buskens E, et al. Scaling the sickness impact profile using item response theory: an exploration of linearity, adaptive use, and patient driven item weights. *J Clin Epidemiol*. 2004;57:66-74.
- Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. *Clin Nephrol*. 2005;63(5):327-334.

- Lippi G, Franchini M, Falavaro EJ. Thrombotic complications of erythropoiesis-stimulating agents. *Semin Thromb Hemost.* 2010;36(5):537-549.
- Locatelli F, Del Vecchio L, Andrulli S. The modality of dialysis treatment: does it influence the response to erythropoietin treatment? *Nephrol Dial Transplant.* 2001;16:1971-1974.
- Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. *Kidney Int.* 2001;60:741-747.
- Locatelli F, Baldamus CA, Villa G, Ganea A, deFrancisco AM. A rationale for an individualized administration frequency of epoetin β : a pharmacological perspective. *Nephrol Dial Transplant.* 2002;17[Suppl 6]:13-16.
- Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin β : results from a randomized, multicenter, therapeutic-equivalence study. *Am J Kidney Dis.* 2002;40(1):119-125.
- Locatelli F, Andrulli S, Memoli B, Mafferi C, Del Vecchio L, Aterini S, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. *Nephrol Dial Transplant.* 2006;21:991-998.
- Locatelli F, Villa G, de Francisco ALM, Albertazzi A, Adroque HJ, Dougherty FC, Beyer U. Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration. *Curr Med Res Opin.* 2007;23(5):969-979.
- Locatelli F, Villa G, Messa P, Filippini A, Cannella G, De Ferrari G, et al. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. *J Nephrol.* 2008;21:412-420.
- Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). *Nephrol Dial Transplant.* 2009;24:348-354.
- Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, MacDougall IC, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp® therapy (TREAT) study. *Nephrol Dial Transplant.* 2010;25:2846-2850.
- Locatelli F, Del Vecchio L, Casartelli D. Darbepoetin alfa and chronic kidney disease. *N Engl J Med.* 2010;362(7):654-655.
- Locatelli F, Mann JFE, Aldigier J-C, Guajardo DS, Schmidt R, Van Vlem B, et al. C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. *Clin Nephrol.* 2010;73(20):94-103.
- London GM, Fabiani F, Marchais SJ, De Vernejoul M, Guerin AP, Safar ME, et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. *Kidney Int.* 1987;31:973-980.
- London GM, Marchais SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. *Kidney Int.* 2003;63(84):S88-S93.
- López-Gómez JM, Portolés JM, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. *Kidney Int.* 2008;74(Suppl 111):S75-S81.
- Lorenzo V, Hernandez D, Dominguez M, Rodriguez A, Torres A. Oxalosis as a cause of absolute resistance to rHuEpo in chronic haemodialysis patients. *Nephrol Dial Transplant.* 1992;1163-1164.
- Losekann A, Ureña P, Khiraoui F, Casadevall N, Zins B, Bererhi L, et al. Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin. *Nephrol Dial Transplant.* 1990;5:258-263.
- Lu WX, Jones-Burton C, Zhan M, Salzberg DJ, Moore J Jr, Fink JC. Survival benefit of recombinant human erythropoietin administration prior to onset of end-stage renal disease: variations across surrogates for quality of care and time. *Nephron Clin Pract.* 2005;101(2):c79-86.
- Ludwig H, Fritz E, Leitgeb C, Pecherstorfer M, Samonigg H, Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. *Blood.* 1994;84:1056-1063.
- Lui SF, Chung WWM, Leung CB, Chan K, Lai, KN. Pharmacokinetics and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Clin Nephrol.* 1990;33(1):47-51.
- Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Clin Nephrol.* 1991;36(5):246-251.
- Lui SF, Wong KC, Li PKT, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. *Am J Nephrol.* 1992;12:55-60.
- Lundin AP, Akerman MJ, Chesler RM, Delano BG, Goldberg N, Stein RA, Friedman EA. Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. *Nephron.* 1991;58:315-319.
- Lust SA, Subar M, Faris R, Lin W, Weaver J, Tully L. A retrospective review of erythrocyte stimulating agents (ESA) usage in pharmacy claims data. <http://ash.confex.com/ash/2009/webprogram/Paper24741.html>
- Macdonald R. Red cell 2, 3-diphosphoglycerate and oxygen affinity. *Anaesthesia.* 1977;32:544-553.
- Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. *Lancet.* 1989;425-427.

- Macdougall IC, Roberts DE, Coles GA. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). *Clin Pharmacokinet.* 1991;20(2):99-113.
- Macdougall IC, Jones JM, Robinson MI, Miles JB, Coles GA, Williams JD. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. *Contrib Nephrol.* 1991;88:81-86;discussion 152-158.
- Macdougall IC. Poor response to erythropoietin: practical guidelines on investigation and management. *Nephrol Dial Transplant.* 1995;10:607-614.
- Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. *J Am Soc Nephrol.* 1999;10(11):2392-2395.
- Macdougall IC. Poor response to erythropoietin. *Br Med J.* 1995;310:1424-1425.
- Macdougall IC, Tucker B, Thompson J, Tomson CRV, Baker LRI, Raine AEG. A randomized controlled study of iron supplementation in patients treated with erythropoietin. *Kidney Int.* 1996;50:1694-1699.
- Macdougall IC. Strategies for iron supplementation: oral versus intravenous. *Kidney Int.* 1999;55(suppl 69):S61-S66.
- Macdougall IC. Hyporesponsiveness to anemia therapy—what are we doing? *Perit Dial Int.* 2001;21(suppl 3):S225-S230.
- Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. *Nephrol Dial Transplant.* 2002;17(Suppl 11):39-43.
- Macdougall IC, Cooper AC. The inflammatory response and epoetin sensitivity. *Nephrol Dial Transplant.* 2002;17(Suppl 1):48-52.
- Macdougall IC. CREATE: new strategies for early anaemia management in renal insufficiency. *Nephrol Dial Transplant.* 2003;18(suppl2):ii13-ii16.
- Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. *Nephrol Dial Transplant.* 2003;18:576-581.
- Macdougall IC. CERA (Continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. *Current Hematology Rep.* 2005;4(6):436-440.
- Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (c.e.r.a.) in patients with chronic kidney disease. *Clin J Am Soc Nephrol.* 2006;1:1211-1215.
- Macdougall IC, Temple RM, Kwan JTC. Is early treatment of anaemia with epoetin- α beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. *Nephrol Dial Transplant.* 2007;22:784-793.
- Macdougall IC. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. *Current Opin Investig Drugs.* 2008;9(9):1034-1047.
- Macdougall IC, Walker R, Provenzano R, de Alvaro F, Locay HR, Nader PC, et al. C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial. *Clin J Am Soc Nephrol.* 2008;3:337-347.
- Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege A, Froissart M, Eckardt K. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. *N Engl J Med.* 2009;361(19):1848-1855.
- Maeda H, Hitomi Y, Hirata R, Tohyama H, Suwata J, Kamata S, et al. The effect of phlebotomy on serum erythropoietin levels in normal healthy subjects. *Int J Hematol.* 1992;55:111-115.
- Maeda H, Sakaguchi M, Naiki Y, Sumimoto Y, Miyatake J, Matsuda M, et al. Possible involvement of soluble erythropoietin receptor in resistance to erythropoietin in patients with renal anemia. *Am J Nephrol.* 2001;21:426.
- Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. *Leuk Lymphoma.* 2008;49(3):427-438.
- Mahmoud K, Sobh M, El-Shenawy F, Mostafa A, Abo El Magd M, et al. Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against HLA in highly sensitized transplant candidate. *Transplant Proc.* 2004;36:1850-1852.
- Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. *Curr Med Chem.* 2007;14(16):1729-1738.
- Maiorca R, Cancarini GC, Brunori G, Zubari R, Camerini O, Manili L, Movilli E. Comparison of long term survival between hemodialysis and peritoneal dialysis. *Adv Peri Dial.* 1996;12:79-88
- Mange KC, Joffe MM, Feldman HI. Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. *N Engl J Med.* 2001;344:726-731.
- Mann J, Kessler M, Villa G, Martinez-Castelao A, Feldt-Rasmussen B, Cruz J, et al. Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. *Clin Nephrol.* 2007;67(3):140-148.
- Mansuri N, Sheikh IA, Al-Khader AA, Al-Shaikh AM, Huraib SO, Zazgornik J. Reversible uremic deafness: is it correlated with the degree of anemia? *Ann Otol Rhinol Laryngol.* 1997;106:391-393.
- Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. *Curr Opin Clin Nutr Metab Care.* 2002;5:377-383.
- Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI. An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. *Clin Nephrol.* 1997;48(1):34-40.

- Marsden PA. Treatment of anemia in chronic kidney disease—strategies based on evidence. *N Engl J Med.* 2009;361(21):2089-2090.
- Marshall TA, Roberts RJ. In vitro and in vivo assessment of lipid peroxidation of infant nutrient preparations: effect of nutrition on oxygen toxicity. *J Am Coll Nutr.* 1990;9(3):190-199.
- Martín-Guerrero J, Camps-Valls G, Soria-Olivias E, Serrano-López AJ, Pérez-Ruixo J, Jiménez-Torres NV. Dosage individualization of erythropoietin using a profile-dependent support vector regression. *IEEE Trans Biomed Eng.* 2003;50(10):1136-1142.
- Martin KJ. Epoetin delta in the management of renal anaemia: results of a 6-month study. *Nephrol Dial Transplant.* 2007;22:3051-3054.
- Martin KJ. The first human cell line-derived erythropoietin, epoetin- δ (Dynepo®), in the management of anemia in patients with chronic kidney disease. *Clin Nephrol.* 2007;68(1):26-31.
- Massry SG. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism. *Kidney Int.* 1983;24(Suppl 16):S204-S207.
- Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H. Working capacity is increased following recombinant human erythropoietin treatment. *Kidney Int.* 1988;34:525-528.
- McCarty MF. Hyperinsulinemia may boost both hematocrit and iron absorption by up-regulating activity of hypoxia-inducible factor-1 α . *Med Hypotheses.* 2003;61(5-6):567-573.
- McCarthy JT, Regnier CE, Loebertmann CL, Bergstrath EJ. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran—a comparison of two products. *Am J Nephrol.* 2000;20:455-462.
- McClellan DB, Pirie E, Franklin IM. Manual of Optimal Blood Use. EU Optimal Blood Use Project 2010. www.optimalblooduse.eu. Published by Scottish National Blood Transfusion Service 2010.
- McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, et al. The prevalence of anemia in patients with chronic kidney disease. *Curr Med Res Opin.* 2004;20(9):1501-1510.
- McFarlane SI, Chen S, Whaley-Connell AT, Sowers JR, Vassalotti JA, Salifu MO, et al. Prevalence and associations of anemia of CKD: kidney early evaluation program (KEEP) and national health and nutrition examination survey (NHANES) 1999-2004. *Am J Kidney Dis.* 2008;51(4)(Suppl2):S46-S55.
- McGonigle RJS, Huserl F, Wallin JD, Fisher JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. *Kidney Int.* 1984;25:430-436.
- McGonigle RJS, Wallin JD, Shaddock RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. *Kidney Int.* 1984;25:437-444.
- McIntyre CW, Hulme LJ, Taal M, Fluck RJ. Locking of tunneled hemodialysis catheters with gentamicin and heparin. *Kidney Int.* 2004;66:801-805.
- McKenna SP, Hunt SM, McEwen J. Weighting the seriousness of perceived health problems using Thurstone's method of paired comparisons. *Int J Epidemiol.* 1981;10(1):93-97.
- McKenna R, Lamblin C, Pochinco D, Dembinski I, Rush D, Jeffrey J, Grimm P, Nickerson P. Risk of development of anti-hla antibodies following blood transfusions in renal patients. *ASHI* 1998. <http://www.ashi-hla.org/docs/pubs/abstracts/abs98/ab98255.htm> (Accessed May 11, 2011.)
- McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. *Am J Nephrol.* 1990;10:404-408.
- McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. *Am J Nephrol.* 1992;12:162-169.
- McMahon LP, McKenna MJ, Sangkabutra T, Mason K, Sostaric S, Skinner S, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. *Nephrol Dial Transplant.* 1999;14:1182-1187.
- McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. *Nephrol Dial Transplant.* 2000;15:1425-1430.
- McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. *Blood.* 1990;76(9):1718-1722.
- McVicar CM, Colhoun LM, Abrahams JL, Kitson CL, Hamilton R, Medina RJ, et al. Differential modulation of angiogenesis by erythropoiesis-stimulating agents in a mouse model of ischaemic retinopathy. *PLoS ONE.* 2010;5(7):e11870-e11870.
- Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. *Blood.* 1992;80(7):1639-1647.
- MedlinePlus. Hemoglobin. (Accessed March 2011 at <http://www.nlm.nih.gov/medlineplus/ency/article/003645.htm>).
- Mehrotra R. The John F. Maher Award Recipient Lecture 2006. The continuum of chronic kidney disease and end-stage renal disease: challenges and opportunities for chronic peritoneal dialysis in the United States. *Perit Dial Int.* 2007;27:125-130.
- Meier-Kriesche H, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes. *Transplantation.* 2002;74(10):1377-1381.

- Merello Godino JI, Rentero R, Orlandini G, Marcelli D, Ronco C. Results from EuCLiD (European clinical dialysis database): impact of shifting treatment modality. *Int J Artif Organs*. 2002;25(11):1049-1060.
- Metivier F, Marchais SJ, Guerin AP, Pannier B, London GM. Pathophysiology of anaemia: focus on the heart and blood vessels. *Nephrol Dial Transplant*. 2000;15[Suppl 3]: 14-18.
- Meyer JW, Eichhorn K, Vetter K, Christen S, Schleusner E, Klos A, et al. Does recombinant human erythropoietin not only treat anemia but reduce postpartum (emotional) distress as well? *J Perinat Med*. 1995;23:99-109.
- Michael B, Fishbane S, Coyne DW, Agarwal R, Warnock DG. Drug insight: safety of intravenous iron supplementation with sodium ferric gluconate complex. *Nat Clin Pract Nephrol*. 2006;2(2):92-100.
- Middleton D, Martin J, Douglas J, McClelland M. Transfusion of one HLA-DR antigen-matched blood to potential recipients of a renal allograft. *Transplantation*. 1994;58(7):845-848.
- Milutinović S, Plavljanić D, Trkulja V. Comparison of two epoetin brands in anemic hemodialysis patients: results of two efficacy trials and a single-dose pharmacokinetic study. *Fundam Clin Pharmacol*. 2006;1-9.
- Minutolo R, De Nicola L, Bellizzi V, Iodice C, Rubino R, Aucella F, et al. Intra- and post-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients. *Nephrol Dial Transplant*. 2003;18:2606-2612.
- Minutolo R, Chiodini P, Cianciaruso B, Pota A, Bellizzi V, Avino D, et al. Epoetin therapy and hemoglobin level variability in nondialysis patients with chronic kidney disease. *Clin J Am Nephrol*. 2009;4:552-559.
- Mircescu G, Gârneata L, Capusa C, Ursea N. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients. *Nephrol Dial Transplant*. 2006;21(1):120-4. Epub 2005 Sep 6.
- Mircescu G, Gârneata L, Ciocâlțeu A, Golea O, Gherman-Câprioară M, Capsa D, et al. Once-every2-weeks and once-weekly epoetin beta regimens: equivalency in hemodialyzed patients. *Am J Kidney Dis*. 2006;48(3):445-455.
- Modell B, Khan M, Darlison M. Survival in β -thalassaemia major in the UK: data from the UK Thalassaemia Register. *Lancet*. 2000;355:2051-2052.
- Mohan P, Murphy DM, Counihan A, Cunningham P, Hickey DP. The role of intraoperative heparin in cyclosporine treated cadaveric renal transplant recipients. *J Urol*. 1999;162:682-684.
- Mohini R. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. *Semin Nephrol*. 1989;9(1)suppl 1:16-21.
- Molina M, Navarro MJ, de Gracia C, Álvarez G, de Alarcón R, García MÁ. Change in darbepoetin alfa administration schedule affects erythropoiesis-stimulating agent resistance in patients with chronic kidney disease receiving hemodialysis. *Ren Fail*. 2008;30:778-783.
- Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Haromszeki B, Kosa JP, et al. Association between the malnutrition-inflammation score and post-transplant anaemia. *Nephrol Dial Transplant*. 2010;1-7.
- Mokrzycki MH, Jean-Jerome K, Rush H, Zdunek MP, Rosenberg SO. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. *Kidney Int*. 2001;59:1935-1942.
- Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. *Pediatr Transplant*. 2004;8:535-542.
- Moreno F, Aracil FJ, Pérez R, Valderrábano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. *Am J Kidney Dis*. 1996;27(4):548-556.
- Moreno F, Sanz-Guajardo D, López-Gómez JM, Jofre R, Valderrábano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. *J Am Soc Nephrol*. 2000;11:335-342.
- Morris KP, Sharp J, Watson S, Coulthard MG. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. *Arch Dis Child*. 1993;69:580-586.
- Morris KP, Skinner JR, Hunter S, Coulthard MG. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure. *Arch Dis Child*. 1993;68:644-648.
- Morris KP, Hughes C, Hardy SP, Matthews JNS, Coulthard MG. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help? *Nephrol Dial Transplant*. 1994;9:1299-1301.
- Movilli E, Cancarini GC, Cassamali S, Camerini C, Brunori G, Maffei C, Maiorca R. Inter-dialytic variations in blood volume and total body water in uraemic patients treated by dialysis. *Nephrol Dial Transplant*. 2004;19:185-189.
- Movilla E, Pertica N, Camerini C, Cancarini GC, Brunori G, Scolari F, Maiorca R. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. *Am J Kidney Dis*. 2002;39(4):850-853.
- Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. *Am J Nephrol*. 1992;12:303-310.
- Muirhead N, Hodsmann AB. Occult infection and resistance of anaemia to rHuEpo therapy in renal failure. *Nephrol Dial Transplant*. 1990;5:232-234.
- Muirhead N, Hodsmann AB, Hollomby DJ, Cordy PE. The role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.

Nephrol Dial Transplant. 1991;6:342-345.

Muirhead N, Keown PA, Churchill DN, Poulin-Costello M, Gantotti S, Lei L, et al. Dialysis patients treated with Epoetin α show improved exercise tolerance and physical function: a new analysis of the Canadian Erythropoietin Study Group trial. *Hemodial Int*. 2011;15:87-94.

Muirhead N, Laupacis A, Wong C. Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian erythropoietin study group). *Nephrol Dial Transplant*. 1992;7:811-816.

Mujais SK, Story K, Brouillette J, Takano T, Soroka S, Franek C, et al. Health-related quality of life in CKD patients: correlates and evolution over time. *Clin J Am Soc Nephrol*. 2009;4:1293-1301.

Murphy MF, Wallington TB, Kelsey P, Boulton F, Bruce M, Cohen H, et al. Guidelines for the clinical use of red cell transfusions. British Committee for Standards in Haematology, Blood Transfusion Task Force. *Br J Haematol*. 2001;13(1):24-31.

Nagaya H, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Hamaguchi K, et al. Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. *Clin Exp Nephrol*. 2010;14:158-163.

Nakamoto H, Kanno Y, Okada H, Suzuki H. Erythropoietin resistance in patients on continuous ambulatory peritoneal dialysis. *Adv Perit Dial*. 2004;20:111-124.

Nakatsuka K, Hino M, Miki T, Nishizawa Y, Tabata T, Inoue T, Moril H. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus. *Diabetes Care*. 1990;13(11):1130-1131.

National Collaborating Centre for Chronic Conditions. Chronic Kidney Disease. National guidelines for early identification and management in adults in primary and secondary care. Royal College of Physicians. 2008.

National Kidney Foundation. KDOQI™ clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. *Am J Kidney Dis* 2007;49(suppl 2):S1-S180.

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 39: Anaemia management in people with chronic kidney disease. Issue date: September 2006.

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 73: Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care. Issue date: September 2008.

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline 73: Rapid update of Guideline B9. Issue date: March 2011.

Naughton J, Sevelius G, Balke B. Physiological responses of normal and pathological subjects to a modified work capacity test. *J Sports Med Phys Fitness*. 1963;44:201-207.

Navarro JF, Macia ML, Fernlindez CM, Gallego E, Chahin J, Mendez ML, et al. Effects of angiotensin converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysis patients. *Adv Perit Dial*. 1997;13:257-259.

Nephrology Dialysis Transplantation Treatment of Anemia Guidelines. (Accessed March 2011 at http://ndt.oxfordjournals.org/content/19/suppl_2/ii16.full.pdf+html).

Ness PM. *Transfus Med: an overview and update*. *Clin Chem*. 2000;46(8):1270-1276.

Neumayer H, Brockmüller J, Fritschka E, Roots I, Scigalla P, Wattenberg M. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long term IV treatment in patients on maintenance hemodialysis. *Contrib Nephrol*. 1989;76(1):131-142.

Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. *N Engl J Med*. 2005;353:1516-1522.

Neves PL, Morgado E, Faísca M, Carrasqueira H, Baptista A, Silva AP. Nutritional and inflammatory status influence darbepoetin dose in pre-dialysis elderly patients. *Int Urol Nephrol*. 2006;38(3-4):811-3. Epub 2006 Dec 7.

Neves PL, Triviño J, Casaubon F, Romão P, Mendes P, Bexiga I, et al. Elderly patients on chronic hemodialysis: effect of the secondary hyperparathyroidism on the hemoglobin level. *Int Urol Nephrol*. 2002;34:147-149.

Ng Y, Chow M, Lyou J, Hu H, Yung C, Fan C, Huang T. Resistance to erythropoietin: immunohemolytic anemia induced by residual formaldehyde in dialyzers. *Am J Kidney Dis*. 1993;21(2):213-216.

Niaudet P, Dudley J, Charbit M, Gagnadoux M, Macleay K, Broyer M. Pretransplant blood transfusions with cyclosporine in pediatric renal transplantation. *Pediatr Nephrol*. 2000;14:451-456.

Nicol D, MacDonald AS, Lawen J, Belitsky P. Early prediction of renal allograft loss beyond one year. *Transpl Int*. 1993;6:153-157.

Nielsen OJ, Thaysen JH. Response to erythropoietin in anaemic haemodialysis patients. *J Intern Med*. 1989;226:89-94.

Nightingale SC. Erythropoietin available for severe anemia in AIDS patients. *JAMA*. 1989;262(2):184.

Nissenson AR. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. *Am J Kidney Dis*. 1991;18(suppl 1):24-33.

Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. *Am J Kidney Dis*. 2003;42(2):325-330.

- Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. *Am J Kidney Dis.* 2002;40(1):110-118.
- Nissim JA. Plasma iron levels after the intravenous administration of different iron preparations. *J Physiol.* 1952;118(4):63P-64P.
- Nissim JA. Plasma iron levels and urinary iron excretion after the intravenous administration of different iron preparations. *Br J Pharmacol.* 1953;8:371-377.
- Nissim JA. Toxic reactions after intravenous saccharated iron oxide in man. *Br Med J.* 1954 ; 1(4858): 352-356.
- Nitta K, Akiba T, Takei T, Kimata N, Watanabe Y, Oba T, et al. Inflammation and resistance to erythropoietin in hemodialysis patients. *Acta Haematol.* 2002;108:168-170.
- Nomoto Y, Kawaguchi Y, Kubota M, Tagawa H, Kubo K, Ogura Y, et al. A multicenter study with once a week or once every two weeks high dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. *Perit Dial Int.* 1994;14:56-60.
- Nonnast-Daniel B, Creutzig A, Kühn K, Bahlmann J, Reimers E, Brunkhorst R, Caspary L, Koch KM. Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. *Contr. Nephrol.* 1988;66:185-194.
- Nonoguchi H, Izumi Y, Nakayama Y, Kohda Y, Tomita K. Nosocomial dengue in health-care workers. *Lancet.* 2008;371:299.
- Nordkild PK, Graff J, Jørgensen HE, Fugleberg S. Fish oil and antioxidant supplements reduce erythropoietin requirement in haemodialysis patients. *Nephrol Dial Transplant.* 1993; (8)6:569.
- Norman DJ, Fletcher L, Barry J. A randomized study of buffy coat transfusions in cadveric renal transplantation. *Transplant Proc.* 1987;19(1):1967-1970.
- Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life. *Med Care.* 2003;41:582-592.
- Nowicki M, Kokot F, Kokot M, Bar A, Dulawa J. Renal clearance of endogenous erythropoietin in patients with proteinuria. *Int Urol Nephrol.* 1994;26(6):691-699.
- Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. *Ann Thorac Surg.* 2007;84:1556-1563
- O'Neil J, Powell L. Clinical aspects of hemochromatosis. *Semin Liver Dis.* 2005;25(4):381-391.
- Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. *J Cardiovasc Pharmacol.* 1989;13 Suppl 3:S27-S30.
- Opelz G, Pfarr E, Engelmann A, Keppel E. Kidney graft survival rates in black cyclosporine-treated recipients. *Transplant Proc.* 1989;21(6):3918-3920.
- Opelz G, Vanrenterghem Y, Kirste G, Gray DW, Horsburgh T, Lachance JG, et al. Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. *Transplantation.* 1997;63(7):964-967.
- Opelz G. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. *Lancet.* 2005;365:1570-1576.
- Ostrvica E, Mesic E, Ostrvica D, Delic J, Delic-Custendil S, Hukic F, et al. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoetin alpha and beta. *Med Arh.* 2010;64(1):4-6.
- Otsuka M, Yuzawa K, Takada Y, Taniguchi H, Todoroki K, Fukao K, et al. Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. *Nephron.* 2001;88:144-148.
- Ouzouni S, Kouidi E, Grekas D, Deligiannis A. Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. *Clin Rehabil.* 2009;23:53-63.
- Ozdemir FN, Sezer S, Akcay A, Arat Z, Turan M, Gulmus S, Kulah E, Haberal M. Panel reactive antibody positivity and associated HLA antibodies in Turkish renal transplant candidates. *Transpl Immunol.* 2004;12:185-188.
- Padhi D, Ni L, Cooke B, Marino R, Jang G. An extended terminal half-life for darbepoetin alfa. *Clin Pharmacokinet.* 2006;45(5):503-510.
- Paganini EP, Latham d, Abdulhadi M. Practical considerations of recombinant human erythropoietin therapy. *Am J Kidney Dis.* 1989;14(2)supp 1:19-25.
- Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. *Am J Kidney Dis.* 1995;26(2):331-340.
- Painter P, Moore G, Carlson L, Paul S, Myll J, Phillips W, Haskell W. Effects of exercise training plus normalization of hematocrit on exercise capacity and health-related quality of life. *Am J Kidney Dis.* 2002;39(2):257-265.
- Pajek J, Bučar-Pajek M, Grego K, Guček A, Bevc S, Ekart R, et al. Epoetin responsiveness in peritoneal dialysis patients: a multi-center Slovenian study. *Ther Apher Dial.* 2005;9(3):228-232.
- Pankewycz O, Kulaylat M, Fagan L, Matthews B, Kohl R, Laftavi MR. A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. *Transplant Proc.* 2010;42:3537-3541.
- Papatheofanis F, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. *Curr Med Res Opin.* 2006;22(5):837-842.

Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. *Am J Ther.* 2007;14:322-327.

Papavasiliou EC, Gouva C, Siamopoulos KC, Tselepis AD. Erythrocyte PAF-acetylhydrolase activity in various stages of chronic kidney disease: effect of long-term therapy with erythropoietin. *Kidney Int.* 2005;68(1):246-255.

Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, Goudevenos JA, Siamopoulos KC. Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance. *Cardiovasc Drugs Ther.* 2008;22:37-44.

Parfrey PS. Should hemoglobin targets for anemia patients with chronic kidney disease be changed? *Am J Nephrol.* 2010;31:565-566.

Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. *J Am Soc Nephrol.* 2005;16:2180-2189.

Parfrey PS, Vavasour H, Bullock M, Henry S, Harnett JD, Gault MH. Development of a health questionnaire specific for end-stage renal disease. *Nephron.* 1989;52:20-28.

Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. *Nephrol Dial Transplant.* 2000;15:1827-1834.

Pascual J, Teruel JL, Marcén R, Liaño F, Moya JL, Jiménez M, Ortuño J. Hemodynamic and cardiac effects of erythropoietin in patients on regular dialysis. *Int J Artif Organs.* 1992;15(6):349-353.

Pascual J, Teruel L, Moya JL, Liaño F, Jiménez-Mena M, Ortuño J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. *Clin Nephrol.* 1991;35(6):280-287.

Patel TV. ACP Journal club. Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia. *Ann Intern Med.* 2010;152(6):JC3-9.

Pavlović-Kentera V, Clemons GK, Trbojević S, Dimković N, Djukanović L. Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases. *Nephron.* 1990;54:139-143.

Pedersen BK. The disease of physical inactivity-and the role of myokines in muscle-fat cross talk. *J Physiol.* 2009;587.23:5559-5568.

Perazella MA, Khan S. Increased mortality in chronic kidney disease: a call to action. *Am J Med Sci.* 2006;331(3):150-153.

Pereira R, Costa E, Goncalves M, Miranda V, do Sameiro Faria M, Quintanilha A, et al. Neutrophil and monocyte activation in chronic kidney disease patients under hemodialysis and its relationships with resistance to recombinant human erythropoietin and to the hemodialysis procedure. *Hemodial Int.* 2010;14:295-301.

Pérez-Flores I, Coronel F, Cigarrán S, Herrero JA, Calvo N. Relationship between residual renal function, inflammation, and anemia in peritoneal dialysis. *Adv Perit Dial.* 2007;23:140-143.

Pérez-García r, Verde E, Sanz A, Valderrábano F. r-HuEPO resistance and dialysate chloramines contamination in patients on hemodialysis. *Nephron.* 2000;86(2):222-3.

Pérez-Olivia JF, Casanova-González M, García-García I, Porrero-Martin PJ, Valenzuela-Silva CM, Hernández-Montero T, et al. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. *BMC Nephrol.* 2005;23:6(1):5.

Pérez-Ruixo JJ, Krzyzanski W, Bouman-Thio E, Miller B, Jang H, Bai SA. Pharmacokinetics and pharmacodynamics of the erythropoietin mimetibody™ construct CNTO 528 in healthy subjects. *Clin Pharmacokinet.* 2009;48(9):601-613.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in ckd patients with anemia. *Clin J Am Soc Nephrol.* 2009;4:1731-1740.

Pergola PE, Gartenberg G, Fu M, Sun S, Wolfson M, Bowers P. A randomized controlled study comparing once-weekly to every-2-week and every-4-week dosing of epoetin alfa in ckd patients with anemia. *Clin J Am Soc Nephrol.* 2010;5:598-606.

Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, et al. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the renal research institute-ckd study. *Am J Kidney Dis.* 2005;45(4):658-666.

Perrinet M, Décaudin B, Champs B, Heran I, Urbina MA, et al. Chronic dialysis-associated anaemia in end-stage renal disease: analysis of management in two French centres. *J Clin Pharm Ther.* 2010;35:395-400.

Petrányi GG, Réti M, Harsányi V, Szabó J. Immunologic consequences of blood transfusion and their clinical manifestations. *Int Arch Allergy Immunol.* 1997;114:303-315.

Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med.* 2009;361(21):2019-2032.

Pfeffer MA, Burdmann EA, Chen C, Cooper ME, de Zeeuw D, Eckardt K, Ivanovich P, et al. Baseline characteristics in the trial to reduce cardiovascular events with aranesp therapy (TREAT). *Am J Kidney Dis.* 2009;54(1):59-69.

Pfeifer AC, Timmer J, Klingmüller U. Systems biology of JAK/STAT signaling. *Essays Biochem.* 2008;45:109-120.

- Phelan DL, Hibbett S, Wetter L, Hanto DW, Mohanakumar T. Recombinant erythropoietin: does it really effect sensitization? *Transplant Proc.* 1991;23(1):409-410.
- Pisoni RL, Bragg-Gresham JL, Young EW, Akizawa T, Asano Y, Locatelli F. Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). *Am J Kidney Dis.* 2004;44(1):94-111.
- Pisoni RL, Bragg-Gresham JL, Fuller DS, Morgenstern H, Canaud B, Locatelli F, et al. Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the dialysis outcomes and practice patterns study (DOPPS): associations with mortality, patient characteristics, and facility practices. *Am J Kidney Dis.* 2011;57(2):266-275.
- Plant P, McEwen J, Prescott K. Use of the Nottingham health profile to test the validity of census variables to proxy the need for health care. *J Public Health med.* 1996;18(3):313-320.
- Polenakovic M, Sikole A. Is erythropoietin a survival factor for red blood cells? *J Am Soc Nephrol.* 1996;7:1178-1182.
- Pollard WE, Bobbitt RA, Bergner M, Martin DP, Gilson BS. The sickness impact profile: reliability of a health status measure. *Med Care.* 1976;14(2):146-155.
- Pollok M, Bommer J, Gurland HJ, Koch KM, Schoeppe W, Scigalla P, Baldamus CA. Effects of recombinant human erythropoietin treatment in end-stage renal failure patients. *Contrib Nephrol.* 1989;76:201-218.
- Porter JB. Practical management of iron overload. *Br J Haematol.* 2001;115:239-252.
- Portolés JM, de Francisco AL, Górriz JL, Martínez-Castelao A, López-Gómez JM, Arias M, et al. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical perspective study. *Kidney Int.* 2008;74(Suppl 111):S82-S87.
- Potter DE, Portale AA, Melzer JS, Feduska NJ, Garovoy MR, Husing RM, Salvatierra O. Are blood transfusions beneficial in the cyclosporine era? *Pediatr Nephrol.* 1991;5:168-172.
- Pour-Reza-Gholi F, Daneshvar S, Nafar M, Firouzan A, Farrokhi F, Einollahi B. Potential risk factors for hypersensitization reflected by panel-reactive antibodies in dialysis patients. *Transplant Proc.* 2005;37:2936-2938.
- Pouteil-Noble C, Betuel H, Raffaele P, Robert F, Dubernard JM, Touraine JL. The value of platelet transfusions as preparation for kidney transplantation. *Transplantation.* 1991;51(4):777-781.
- Prieto L, Alonso J, Ferrer M, Antó M. Are results of the SF-36 health survey and the Nottingham health profile similar?: a comparison in COPD patients. *J Clin Epidemiol.* 1997;50(4):463-471.
- Prieto L, Alonso J, Lamarca R. Classical test theory versus Rasch analysis for quality of life questionnaire reduction. *Health and Qual Life Outcomes.* 2003;1:27.
- Pritikin N. Optimal dietary recommendations: a public health responsibility. *Prev Med.* 1982;11:733-739.
- Priyadarshi A, Shapiro JI. Erythropoietin resistance in the treatment of the anemia of chronic renal failure. *Semin Dial.* 2006;19(4):273-278.
- Prommool S, Jhangri GS, Cockfield SM, Halloran PF. Time dependency of factors affecting renal allograft survival. *J Am Soc Nephrol.* 2000;11:565-573.
- Provenzano R, Garcia-Mayol L, Suchinda P, Von Hartitzsch B, Woolen SB, Zabaneh R, et al. Once-weekly epoetin alfa for treating the anemia of chronic kidney disease. *Clin Nephrol.* 2004;61(6):392-405.
- Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. *Clin Nephrol.* 2005;64(2):113-123.
- Pussell BA, Walker R (Australian Renal Anaemia Group). Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare? *Nephrology (Carlton).* 2007;12(2):126-129.
- Questions about Blood. <http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/QuestionsaboutBlood/default.htm>. (Accessed May 11, 2011).
- Qureshi BH. Consensus and controversies on HLA matching and crossmatching in transplantation. *Saudi J Kidney Dis Transplant.* 1997;8(2):138-144.
- Rabiner SF. Uremic Bleeding. *Prog Hemost Thromb.* 1972;1:233-250.
- Radtke HW, Claussner A, Erbes PM, Scheuermann EH, Schoeppe W, Koch KM. Serum erythropoietin concentration in chronic renal failure: relationship to degree of anemia and excretory renal function. *Blood.* 1979;54(4):877-884.
- Radtke HW, Erbes PM, Fassbinder W, Koch KM. The variable role of erythropoietin deficiency in the pathogenesis of dialysis anaemia. *Proc Eur Dial Transplant Assoc.* 1977;14:177-183.
- Radtke HW, Frei U, Erbes PM, Schoeppe W, Koch KM. Improving anemia by hemodialysis: effect on serum erythropoietin. *Kidney Int.* 1980;17:382-387.
- Radtke HW, Rege AB, LaMarche MB, Bartos D, Bartos F, Campbell RA, Fisher JW. Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure. *J Clin Invest.* 1981;67:1623-1629.
- Ramirez G, Bittle PA, Rabb HA, Ballester O, Bercu BB. Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary-thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients. *Clin Endocrinol (Oxf).* 1995;43:167-174.
- Rao S, Carter WB, Mapes DL, Kallich JD, Kamberg CJ, Spritzer KL, Hays RD. Development of subscales from the symptoms/problems and effects of kidney

disease scales of the kidney disease quality of life instrument. *Clin Ther.* 2000;22(9):1099-1111.

Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, et al. Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. *JAMA.* 2004;292(13):1555-1562.

Ratajczak J, Majka M, Kijowski J, Baj M, Pan ZK, Marquez LA, Janowska-Wieczork A, Ratajczak MZ. Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. *Br J Haematol.* 2001;115:195-204.

Ratke HW, Frei U, Erbes PM, Schoeppe W, Koch KM. Improving anemia by hemodialysis: effect on serum erythropoietin. *Kidney Int.* 1980;17:382-387.

Ravanan R, Udayaraj U, Steenkamp R, Ansell D. Chapter 5: Demographics and biochemistry profile of kidney transplant recipients in the UK in 2007: national and centre-specific analyses. *Nephron Clin Pract.* 2009;111 (Suppl. 1):c69-c96.

Reed A, Pirsch JD, Armbrust MJ, Burlingham WJ, Knechtle SJ, D'Alessandro AM, Sollinger HW, Kalayoglu M, Belzer FO. A comparison of donor-specific and random transfusions in living-related renal transplantation and their effect on steroid withdrawal. *Transplant Proc.* 1991;23(1):1321-1322.

Rege AB, Ohno Y, Barona J, Fisher JW. Inhibitors of erythroid colony forming cells in sera of azotemic patients with anemia of renal disease. *Proc Clin Dial Transplant Forum.* 1978;8:189-193.

Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. *Nephrol Dial Transplant.* 2010;1-8.

Reilly JT. Idiopathic myelofibrosis: pathogenesis, natural history and management. *Blood Rev.* 1997;11(4):233-242.

Reisaeter AV, Leivestad T, Albrechtsen D, Holdaas H, Hartmann A, Sódal G, Flatmark A, Fauchald P. Pretransplant plasma exchange or immunoadsorption facilities renal transplantation in immunized patients. *Transplantation.* 1995;60(3):242-248.

Reissmann KR, Nomura T, Gunn RW, Brosius F. Erythropoietin response to anemia or erythropoietin injection in uremic rats with or without functioning renal tissue. *Blood.* 1960;16:1411-1423.

Rejman ASM, Grimes AJ, Cotes PM, Mansell MA, Joekes AM. Correction of anaemia following renal transplantation: serial changes in serum immunoreactive erythropoietin, absolute reticulocyte count and red-cell creatin levels. *Br J Haematol.* 1985;61:421-431.

Relative mortality and epoetin alfa dose among hemodialysis patients. *Am J Kidney Dis.* 2008;51(5):865-867.

Remuzzi G, Ingelfinger JR. Correction of anemia-payoffs and problems. *N Engl J Med.* 2006;355(20):2144-2146.

Revicki DA. Relationship between health utility and psychometric health status measures. *Med Care.* 1992;30(5):MS274-MS282.

Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. *Am J Kidney Dis.* 1995;25(4):548-554.

Richardson D. Clinical factors influencing sensitivity and response to epoetin. *Nephrol Dial Transplant.* 2002;17(Suppl 1):53-59.

Richardson D, Bartlett C, Goutcher E, Jones CH, Davison AM, Will EJ. Erythropoietin resistance due to dialysate chloramines: the two-way traffic of solutes in haemodialysis. *Nephrol Dial Transplant.* 1999;14:2625-2627.

Richardson D, Ford D, Gilg J, Williams AJ. UK renal registry 11th annual report: chapter 9 haemoglobin, ferritin and erythropoietin amongst patients receiving dialysis in the UK in 2007: national and centre-specific analysis. *Nephron Clin Pract.* 2009;111(suppl 1):c149-183.

Riegersperger M, Sengoelge G, Köller M, Grossmann N, Benesch T, Sunder-Plassmann G. Anemia in patients with Wegener's granulomatosis. *Clin Nephrol.* 2007;67(3):149-156.

Rijk Y, Raaijmakers R, van de Kar N, Schröder C. Intraperitoneal treatment with darbepoetin for children on peritoneal dialysis. *Pediatr Nephrol.* 2007;22:436-440.

Ripamonti V, Racca V, Calvo MG, Castiglioni P, Ferratini M. Angiotensin-converting enzyme inhibitors slow recovery from anemia following cardiac surgery. *Chest.* 2006;130:79-84.

Ritz E, Laville M, Bilous RW, et al. Target Level for Hemoglobin Correction in Patients With Diabetes and CKD: Primary Results of the Anemia Correction in Diabetes (ACORD) Study. *Am J Kidney Dis.* 2007;49(2):194-207.

Robertson, BC, Curtin C. Effects of EPO therapy on backfiltration of dialysate in high flux dialysis. *ASAIO Trans.* 1990;36:M447-M452.

Rocha JL, Gentil MA, Gili M, Gil L, Cabello V, Bernal G. Continuous intravenous intradialysis versus intravenous postdialysis erythropoietin therapy in chronic haemodialysis patients: a randomized, controlled, crossover study. *Nephrol Dial Transplant.* 1998;13:89-92.

Roche A, Macdougall IC, Walker RG. Haemoglobin fluctuations in patients on haemodialysis treated with ESAs: clinical observations from two centres. *Curr Med Res Opin.* 2009;25(12):2971-2976.

Roe DJ, Harford AM, Zager PH, Wiltbank TB, Kirlin L, Della Valle A, Van Wyck DB. Iron utilization after iron dextran administration for iron deficiency in patients with dialysis-associated anemia: a prospective analysis and comparison of two agents. *Am J Kidney Dis.* 1996;28(6):855-860.

Roger SD, Stewart JH, Harris DC. Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common. *Nephron.* 1991;58:33-36.

- Roger SD, McMahon LP, Clarkson A, Disney A, Harris D, Hawley C, et al. Effects of early and late intervention with epoetin α on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. *J Am Soc Nephrol.* 2004;15:148-156.
- Roger SD, Levin A. Epoetin trials: randomized controlled trials don't always mimic observational data. *Nephrol Dial Transplant.* 2007;22(3):684-686.
- Roger SD, Suranyi MG, Walker RG. A randomized, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease. *Curr Med Res Opin.* 2008;24(8):2181-2187.
- Roman RM, Lobo PI, Taylor RP, Goodkin DA, Labrecque J, Powers KL, Bolton WK. Prospective study of the immune effects of normalizing the hemoglobin concentration in hemodialysis patients who receive recombinant human erythropoietin. *J Am Soc Nephrol.* 2004;15:1339-1346.
- Romero R, Novoa D, Perez-Freiria A, Arcocha V, Alonzo R, Arza D, Lens XM, Sanchez-Guisande D. Resistance to recombinant human erythropoietin in a hemodialysis patient with lupus reactivation. *Nephron.* 1995;69:343-344.
- Rosenblatt SG, Drake S, Fadem S, Welch R, Lifschitz MD. Gastrointestinal blood loss in patients with chronic renal failure. *Am J Kidney Dis.* 1982;1(4):232-236.
- Rosenlöf K, Fyhrquist F, Tenhunen R. Erythropoietin, aluminum, and anaemia in patients on haemodialysis. *Lancet.* 1990;335:247-249.
- Ross RP, McCrea JB, Besarab A. Erythropoietin response to blood loss in hemodialysis patients is blunted but preserved. *ASAIO J.* 1994;40:M880-M885.
- Rossert J, Eckardt K. Erythropoietin receptors; their role beyond erythropoiesis. *Nephrol Dial Transplant.* 2005;20:1025-1028.
- Rossert J, Gassmann-Mayer C, Frei D, McClellan W. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. *Nephrol Dial Transplant.* 2007;22:794-800.
- Rossert J, Levin A, Roger SD, Hörl WH, Fouqueray B, Gassmann-Mayer C, et al. Effect of early correction of anemia on the progression of CKD. *Am J Kidney Dis.* 2006;47(5):738-750.
- Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. *Am J Kidney Dis.* 1994;24(5):777-784.
- Rubin R. Kidney doctors question dialysis guidelines. *USA Today.* 9/13/2009.
- Ryan MH, Heavner GA, Brigham-Burke M, McMahon F, Shanahan MF, Gunturi SR, Sharma B, Farrell FX. An in vivo model to assess factors that may stimulate the generation of an immune reaction to erythropoietin. *Int Immunopharmacol.* 2006;6:647-655.
- Sahin G, Acikaliin MF, Yalcin AU. Erythropoietin resistance as a result of oxalosis in bone marrow. *Clin Nephrol.* 2005;63(5):402-404.
- Salmonson T. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. *Scand J Urol Nephrol Suppl.* 1990;Suppl 129:1-66.
- Salmonson T, Danielson BF, Grahnén A, Wikström B. Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. *J Intern Med.* 1990;228:53-57.
- Salmonson T, Danielson BF, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. *Br J Clin Pharmacol.* 1990;29:709-713.
- Saltissi D, Coles GA, Napier JAF, Bentley P. The hematological response to continuous ambulatory peritoneal dialysis. *Clin Nephrol.* 1984;22(1):21-27.
- Samtleben W, Baldamus CA, Bommer J, Grützmacher P, Nonnast-Daniel B, Sciagalla P, Gurland HJ. Indications and contraindications for recombinant human erythropoietin treatment. *Contrib Nephrol.* 1989;76:193-218.
- Sandhu A, Soman S, Hudson M, Besarab A. Managing anemia in patients with chronic heart failure: what do we know? *Vasc Health Risk Manag.* 2010;6:237-252.
- Santoro A, Canova C. Anemia and erythropoietin treatment in chronic kidney diseases. *Minerva Urol Nefrol.* 2005;57:23-31.
- Saracho Rotaache R. Is CERA therapy every 2-4 weeks worse than usual EPO therapy 1-3 times per week? *Nefrologia.* 2008;28(Suppl 2):28-29.
- Sargent J, Acchiardo SR. Iron requirements in hemodialysis. *Blood Purif.* 2004;22:112-123.
- Saudan P, Halabi G, Perneger T, Wasserfallen J, Wauters J, Martin P. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. *J Nephrol.* 2006;19:91-96.
- Sautner T, Gnant M, Banhegyi C, Wamser P, Göttinger P, Steininger R, Mühlbacher F. Risk factors for development of panel reactive antibodies and their impact on kidney transplantation outcome. *Transplant Int.* 1992;5[Suppl 1]:S116-S120.
- Sav T, Tokgoz B, Sipahioglu M, Devenci M, Sari I, Oymak O, Utas C. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? *Ren Fail.* 2007;29:423-426.
- Sayegh MH, Colvin RB. Case 8-2003: A 35-year-old man with early dysfunction of a second renal transplant. *N Engl J Med.* 2003;348(11):1033-1044.
- Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF. Clinical consequences of acquired transfusional iron overload in adults. *New Eng J Med.* 1981;304:319-324.
- Schaller R, Sperschneider H, Thieler H, Dutz W, Hans S, Voigt D, et al. Differences in intravenous and subcutaneous application of recombinant human

erythropoietin: a multicenter trial. *Artif Organs*. 1994;18(8):552-558.

Schärer K, Klare B, Braun A, Dressel P, Gretz N. Treatment of renal anemia by subcutaneous erythropoietin in children with preterminal chronic renal failure. *Acta Paediatr*. 1993;82(11):953-958.

Schellekens H. Assessing the bioequivalence of biosimilars. *Drug Discov Today*. 2009;14(9/10):495-499.

Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. *Nat Biotechnol*. 2006;24(6):613-614.

Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. *Nephrol Dial Transplant*. 2006;21:2841-2845.

Schiffli H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultrapure high-flux haemodialysis. *Eur J Med Res*. 2007;12:26-33.

Schiller GJ, Berkman SA. Hematologic aspects of renal insufficiency. *Blood Rev*. 1989;3:141-146.

Schmidt B, Ward RA. The impact of erythropoietin on hemodialyzer design and performance. *Artif Organs*. 1989;13(1):35-42.

Schmitt CP, Nau B, Brummer C, Rosenkranz J, Schaefer F. Increased injection pain with darbepoetin- α in paediatric dialysis patients. *Nephrol Dial Transplant*. 2006;21:3520-3524.

Schmitz SA, Taupitz M, Wagner S, Coupland SE, Gust R, Nikolova A, Wolf KJ. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques. *Invest Radiol*. 2002;37(7):405-411.

Schollmeyer P, Lubrich-Birkner I, Steinhauer HB. Effect of recombinant human erythropoietin on anemia and dialysis: efficiency in patients undergoing CAPD. *Contrib Nephrol*. 1990;87:95-104.

Schröer RW, Gottschalk CW, eds. *Diseases of the Kidney*. Fourth edition. Boston: Little, Brown, and Company. 1988.

Schröer RW, Ed. *Diseases of the Kidney and Urinary Tract*. Eighth edition. Philadelphia: Lippincott William, and Wilkins. 2006

Schuster SJ, Koury ST, Bohrer M, Salceda S, Caro J. Cellular sites of extrarenal and renal erythropoietin production in anaemic rats. *Br J Haematol*. 1992;81:153-159.

Schwartz AB, Kahn SB, Kelch B, Kim KE, Pequignot E. RBC improved survival due to recombinant human erythropoietin explains effectiveness of less frequent, low dose subcutaneous therapy. *Clin Nephrol*. 1992;38(5):283-289.

Schwartz AB, Kelch B, Terzian L, Prior J, Kim KE, Pequignot E, Kahn SB. One year of rHuEPO therapy prolongs RBC survival and may stabilize RBC membranes despite natural progression of chronic renal failure to uremia and need for dialysis. *ASAIO Trans*. 1990;36(3):M691-696.

Schwartz AB, Prior JE, Mintz GS, Kim KE, Kahn SB. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin. *Transplant Proc*. 1991;23(2):1827-1830.

Scigalla P. Effect of recombinant human erythropoietin treatment on renal anemia and body growth of children with end-stage renal disease. *Contrib Nephrol*. 1991;201-214.

Scigalla P. Reasons for differences in dose requirements of recombinant human erythropoietin in haemodialysis patients. *Contrib Nephrol*. 1990;82:55-64.

Scornik JC, Pfaff WW, Howard RJ, Fennell RS, Ramos E, Peterson JC, Neiberger R. Increased antibody responsiveness to blood transfusions in pediatric patients. *Transplantation*. 1994;58(12):1361-1365.

Sekili S, McCay PB, Li X, Zughaib M, Sun J, Tang L, Thornby JI, Bolli R. Direct evidence that the hydroxyl radical plays a pathogenetic role in myocardial "stunning" in the conscious dog and demonstration that stunning can be markedly attenuated without subsequent adverse effects. *Circ Res*. 1993;73:705-723.

Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. *Kidney Int*. 2011;1-7.

Selm SB. Prevalence of hepatitis C virus infection among hemodialysis patients in a single center in Yemen. *Saudi J Kidney Dis Transplant*. 2012;21(6):1165-1168.

Sezer S, KÜlah E, Özdemir FN, Tütal E, Arat Z, Haberal M. Clinical consequences of intermittent elevation of c-reactive protein levels in hemodialysis patients. *Transplant Proc*. 2004;36:38-40.

Sezer S, Özdemir FN, Turan M, Güz G, Haberal A, Kaya S, Bilgin N. Comparison of panel reactive antibody levels with clinical and laboratory parameters in end-stage renal disease patients. *Transplant Proc*. 1998;30:844-845.

Sezer S, Özdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. *Artif Organs*. 2002;26(4):366-370.

Shafi T, Jaar BG, Plantinga LC, Fink NE, Sadler JH, Parekh RS, et al. Association of residual urine output with mortality, quality of life, and inflammation in incident hemodialysis patients: the choices for healthy outcomes in caring for end-stage renal disease (CHOICE) study. *Am J Kidney Dis*. 2010;56(2):348-358.

Shand BI, Buttmore AL, Hurrell MA, Wells JE, Inkster IA, Bailey RR, et al. Hemorheology and fistula function in home hemodialysis patients following erythropoietin treatment: a prospective placebo-controlled study. *Nephron*. 1993;64:53-57.

- Shander A, Sazama K. Clinical consequences of iron overload from chronic red blood cell transfusions, its diagnosis, and its management by chelation therapy. *Transfusion*. 2010;50:1144-1155.
- Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: perioperative indications, adverse effects, and cost analysis. *Anesth Analg*. 2000;90:1315-1323.
- Sharples EJ, Varaganam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. *Perit Dial Int*. 2006;26:64-68.
- Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, et al. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. *Leukemia*. 2008;22:87-95.
- Shigematsu T, Takami H, Shimizu T, Shimoyama H, Kim S, Hirose S, et al. Efficacy of once-weekly intravenous administration of epoetin-β as a maintenance treatment for anemia in Japanese hemodialysis patients: a multicenter, open-label clinical study. *Ther Apher Dial*. 2008;12(6):469-474.
- Shinaberger JH, Miller JH, Gardner PW. Erythropoietin alert: risks of high hematocrit hemodialysis. *ASAIO Trans*. 1988;34:179-184.
- Shiozawa Y, Jung Y, Ziegler AM, Pedersen EA, Wang J, Wang Z, et al. Erythropoietin couples hematopoiesis with bone formation. *PLoS ONE*. 2010;5(5):1-14. Accessed via www.plosone.org (e10853) (Accessed May 11, 2011).
- Siamopoulos KC, Gouva C, Katopodis KP, Tzallas C, Nikolopoulos P, Papavasiliou EC, Tselepis AD. Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD. *Am J Kidney Dis*. 2006;48(2):242-249.
- Sikole A, Efrernov DG, Dinovski A, Efremov GD, Polenakovic M. Hemoglobin F levels in end-stage renal disease patients after correction of anemia with erythropoietin. *Nephron*. 1993;65(3):482-484.
- Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. *Artif Organs*. 1993;17(12):977-984.
- Sikole A, Stojanovic A, Polenakovic M, Petrusavska G, Sadikario S, Saso R, Jovanovski M. How erythropoietin affects bone marrow of uremic patients. *Am J Nephrol*. 1997;17(2):128-136.
- Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. *J Am Coll Cardiol*. 2001;37(7):1775-1780.
- Silverstein SB, Rodgers GM. Parenteral iron therapy options. *Am J Hematol*. 2004;76(11):74-78.
- p>Simon GE, Bove JR. The potassium load from blood transfusion. *Postgrad Med*. 1971;49(6):61-64.
- Simon TL, Snyder EL, Solheim BG, Stowell CP, Strauss RG, Petrides M, Eds. *Rossi's Principles of Transfus Med*. Fourth edition. Hoboken, NJ: Wiley-Blackwell for AABB. 2009.
- Singh AK, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med*. 2006;355(20):2085-2098.
- Singh AK, Szczech L, Tang K, Barnhart H, Sapp S, Wolfson M, Reddan D. Anaemia of CKD—the CHOIR study revisited. *Nephrol Dial Transplant*. 2007;22(7):1806-1810.
- Singh AK, Himmelfarb J, Szczech LA. Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia. *J Am Soc Nephrol*. 2009;20(7):1436-1443.
- Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? *Curr Opin Nephrol Hypertens*. 2010;19(5):420-424.
- Singh J, Malani AK, Pabla M. Eculizumab in paroxysmal nocturnal hemoglobinuria. *New Engl J Med*. 2006;355(26):2786-2788.
- Singh NP, Aggarwal L, Singh T, Anuradha S, Kohli R. Anaemia, iron studies and erythropoietin in patients of chronic renal failure. *J Assoc Physicians India*. 1999;47(3):284-290.
- Sintonen H. The 15D instrument of health-related quality of life: properties and applications. *Ann Med*. 2001;33(5):328-336.
- Sirken G, Kung S, Raja R. Decreased erythropoietin requirements in maintenance hemodialysis patients with statin therapy. *ASAIO J*. 2003;49:422-425.
- Sirken G, Raja R, Rizkala AR. Association of different intravenous iron preparations with risk of bacteremia in maintenance hemodialysis patients. *Clin Nephrol*. 2006;66(5):348-356.
- Sitter T, Bergner A, Schiffel H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. *Nephrol Dial Transplant*. 2000;15(8):1207-1211.
- Sjajeem FA, Akeel N, Alfi A, Harbi A, Tarif N, Souqiyeh MZ. Darbepoetin use for the treatment of anemia in hemodialysis patients in Saudia Arabia. *Saudi J Kidney Dis Transplant*. 2006;17(3):365-372.
- Sklar AH, Narsipurs S. Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Undergoing Hemodialysis and Receiving Epoetin. *N Eng J Med*. 1988;339:2023-2034
- Smith WB, Dowell JA, Pratt RD. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with

chronic kidney disease. *Clin Ther.* 2007;29(7):1368-1380.

Sobota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. *Contrib Nephrol.* 1989;76:166-78.

Sobota JT. The role of recombinant human erythropoietin in homologous transfusion avoidance. *Contrib Nephrol.* 1991;88:334-350.

Sohmiya M, Kakiba T, Kato Y. Therapeutic use of continuous subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. *Eur J Endocrinol.* 1998;139(4):367-370.

Solar P, Feldman L, Jeong JY, et al. Erythropoietin treatment of human ovarian cancer cells results in enhanced signaling and a paclitaxel-resistant phenotype. *Int J Cancer.* 2008;122(2):281-288.

Solar P, Koval J, Mikes J, et al. Erythropoietin inhibits apoptosis induced by photodynamic therapy in ovarian cancer cells. *Mol Cancer Ther.* 2008;7(8):2263-2271. Epub 2008 Aug 6.

Solomon SD, Uno H, Lewis EF, Eckardt K, Lin J, Burdman EA, et al. Erythropoietic response and outcomes in kidney disease and Type 2 diabetes. *N Engl J Med.* 2010;363(12):1146-1155.

Soosay A, O'Neill D, Counihan A, Hickey D, Keogan M. Causes of sensitization in patients awaiting renal transplantation in Ireland. *Ir Med J.* 2003;96(4):109-112.

Sorace J, Wong H, Worrall C, Kelman J, Saneinejad S, MaCurdy T. The complexity of disease combinations in the medicare population. *Population Health Management.* 2011;17:1-6.

Special Issue: KDIGO clinical guideline for the care of kidney transplant recipients. *Am J Transplant.* 2009;9:S1-S155.

Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, et al. C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks. *Am J Nephrol.* 2008;28:280-289.

St. Peter WL, Lewis MJ, Macres MG. Pain comparison after subcutaneous administration of single-dose formulation versus multidose formulation of Epogen in hemodialysis patients. *Am J Kidney Dis.* 1998;32(3):470-474.

St. Peter WL, Manley HJ, Sullivan S. Managed care to medicare: sharing the burden of chronic kidney disease. *Supplement to Journal of Managed Care Pharmacy.* 2007;13(9):s1-s24.

Stansfield SA, Roberts R, Foot SP. Assessing the validity of the SF-36 general health survey. *Qual Life Res.* 1997;6:217-224.

Stenvinkel P. New insights on inflammation in chronic kidney disease-genetic and non-genetic factors. *Nephro Thur.* 2006;2:111-119.

Stenvinkel P, Bárány P. Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress. *Nephrol Dial Transplant.* 2002;17(Suppl 5):32-37.

Stivelman JC. Resistance to recombinant human erythropoietin therapy: a real clinical entity? *Semin Nephrol.* 1989;9(1):8-11.

Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, Lechner K. Recombinant human erythropoietin activates a broad spectrum of progenitor cells. *Kidney Int.* 1990;37:150-156.

Stockenhuber F, Loibl U, Gottsauner-Wolf M, Jahn C, Manker W, Meisl TF, Balcke P. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. *Nephron.* 1991;59:399-402.

Stoffel MP, Haverkamp H, Kromminga A, Lauterbach KW, Baldamus CA. Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. *Nephrol Clin Pract.* 2007;105:c90-c98.

Stojcheva-Taneva OO, Polenakovic MH. Autonomic neuropathy in hemodialysis patients treated with recombinant human erythropoietin. *Int J Artif Organs.* 1996;19:574-577.

Stone WJ, Graber SE, Krantz SB, Dessypris EN, O'Neil VL, Olsen NJ, Pincus TP. Treatment of the anemia of predialysis patients with recombinant human erythropoietin: a randomized, placebo-controlled trial. *Am J Med Sci.* 1988;296(3):171-179.

Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. *Nephrol Dial Transplant.* 2001;16(5):967-974.

Stramer SL, Hollinger FB, Katz LM, Kleinman S, Metzel PS, Gregory KR, Dodd RY. Emerging infectious disease agents and their potential threat to transfusion safety. *Transfusion.* 2009;49:1S-29S.

Strippoli GF. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. *Trials.* 2010;11:70.

Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD003967. DOI: 10.1002/14651858.CD003967.pub2.

Stubbs JR. Transfusion-related acute lung injury, an evolving syndrome: the road of discovery, with emphasis on the role of the mayo clinic. *Transfus Med Rev.* 2011;25(1):66-75.

Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable

iron. *Kidney Int.* 2005;67:1161-1170.

Sturm B, Goldenberg H, Scheiber-Mojdehkar. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. *Eur J Biochem.* 2003;270:3731-3738.

Subpoena information in Amgen SEC 10-K Annual Report (filed 2/25/2011) and 10-Q quarterly Reports (filed 5/7/2010, 8/9/2010).

Sudhaker Rao D, Shih M, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. *N Engl J Med.* 1993;328:171-175.

Sulowicz W, Locatelli F, Ryckelynck J, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. *Clin J Am Soc Nephrol.* 2007;2:637-646.

Summerfield GP, Gyde OHB, Forbes AMW, Goldsmith HJ, Bellingham AJ. Haemoglobin concentration and serum erythropoietin in renal dialysis and transplant patients. *Scand J Haematol.* 1983;30:389-400.

Sun CH, Ward HJ, Paul WL, Koyle MA, Yanagawa N, Lee DB. Serum erythropoietin levels after renal transplantation. *N Engl J Med.* 1989;321:151-157.

Sundal E, Businger J, Kappeler A. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. *Nephrol Dial Transplant.* 1991;6:955-965.

Sunder-Plassmann, Hörl WH. Importance of iron supply for erythropoietin therapy. *Nephrol Dial Transplant.* 1995;10:2070-2076.

Sunder-Plassmann, Hörl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. *Nephrol Dial Transplant.* 1996;11:1797-1802.

Sungur C. Resistance to human recombinant erythropoietin in hypothyroidism. *Acta Haematol.* 1992;88:162.

Sungur C. Bone marrow involvement in systemic amyloidosis: another mechanism for erythropoietin resistance. *Nephron.* 1993;63:232-233.

Suzuki M. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment. *Contrib Nephrol.* 1990;82:65-71.

Suzuki M, Hirasawa Y, Hirashima K, Arakawa M, Odaka M, Ogura Y, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease. *Contrib Nephrol.* 1989;76:179-92; discussion 212-218.

Swain RA, Kaplan B, Montgomery E. Iron deficiency anemia. *Post Grad Med.* 1996;100(5):181-193.

Szcech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. *Kidney Int.* 2008;74(6):791-798.

Szcech LA, Barnhart HX, Sapp S, Felker GM, Hernandez A, Reddan D, et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. *Kidney Int.* 2010;77(3):239-246.

Szcech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival. *Ann Intern Med.* 1998;128:817-826.

Szenajch J, Wcislo G, Jeong J, Szczylik C, Feldman L. The role of erythropoietin and its receptor in growth, survival and therapeutic response of human tumor cells. From clinic to bench-a critical review. *Biochim Biophys Acta.* 2010;1806:82-95.

Ter Wee PM, deKoter Y, van der Veer O, van Vliet MH. Immediate pain sensation is less with subcutaneous epoetin- β compared to subcutaneous darbepoietin- α . *Clin Nephrol.* 2009;72(3):177-180.

Taaning E, Simonsen AC, Hjelms E, Svejgaard A, Morling N. Platelet Alloimmunization after Transfusion. *Vox Sang.* 1997;72:238-241.

Tan A. Recombinant human erythropoietin (rHuEPO): quality of life and other considerations. *J CANNT.* 1990: Summer 13-14.

Targ D, Huang T, Chen TW, Fan CY, Chang JG. Resistance to recombinant human erythropoietin treatment in thalassaemic patients on chronic haemodialysis; a real clinical entity? *Nephrol Dial Transplant.* 1995;10(12):2281-2285.

Targ D, Chen T, Huang T. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. *Am J Nephrol.* 1995;15:230-237.

Targ D, Huang T. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. *Nephrol Dial Transplant.* 1998;13:2867-2872.

Targ D, Huang T. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity. *Am J Nephrol.* 1998;18:1-8.

Taylor JE, Belch JJ, Fleming W, Macter RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. *Clin Nephrol.* 1994;41(5):297-302.

Taylor JE, Belch JJ, McLaren M, Henderson IS, Stewart WK. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. *Kidney Int.* 1993;44:182-190.

Taylor JE, Henderson IS, Stewart WK, Belch JJ. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. *Lancet.* 1991;338:1361-1362.

Taylor JE, McLaren M, Mactier RA, Henderson IS, Stewart WK, Belch JJ. Effect of dialyzer geometry during hemodialysis with cuprophane membranes. *Kidney Int.* 1992;42(2):442-7.

- Taylor JE, Henderson IS, Mactier RA, Stewart WK. Effects of withdrawing erythropoietin. *Br Med J.* 1991;302:272-273.
- Teehan BP, Benz RL, Sigler MH, Brown JM. Early intervention with recombinant human erythropoietin therapy. *Semin Nephrol.* 1990;10(2):28-34.
- Teehan BP, Krantz S, Stone WA, Graber SE, Abraham P, Dauer A, et al. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. *Am J Kidney Dis.* 1991;18(1):50-59.
- Teplan V, Schüick O, Knotek A, Hajny J, Horáčková M, Kvapil M. Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study. *Am J Kidney Dis.* 2003;41(S1):S26-S30.
- Teplan V, Schüick O, Knotek A, Hajny J, Horáčková M, Skibová J, Malý J. Effects of low-protein diet supplemented with ketoacids and erythropoietin in chronic renal failure: a long-term metabolic study. *Ann Transplant.* 2001;6(1):47-53.
- Terasaki PI. Factors influencing cadaver kidney transplantation outcome in the cyclosporine era. *Clin Transpl.* 1988:131-145.
- Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. *Am J Transplant.* 2004;4(3):438-443.
- Ternes N, Scheiber-Mojdehkar B, Landgraf G, Goldenberg H, Sturm B. Iron availability and complex stability of iron hydroxyethyl starch and iron dextran-a comparative in vitro study with liver cells and macrophages. *Nephrol Dial Transplant.* 2007;22:2824-2830.
- Teruel J, Marcen R, Ocaña J, Fernández-Lucas M, Rivera M, Tabernero G, Ortuño. Clinical significance of c-reactive protein in patients on hemodialysis: a longitudinal study. *Nephron Clin Pract.* 2005;100:c140-c145.
- Thanakitcharu P, Siriwiwatanakul N. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia. *J Med Assoc Thai.* 2007;90(12):2574-2586.
- Thawani N, Tam M, Stevenson MM. STAT6-mediated suppression of erythropoiesis in an experimental model of malarial anemia. *Haematologica.* 2008;94(2).
- Thilly N, Boini S, Loos-Ayav C, Kessler M, Briancon S, Frimat L. Factors associated with anemia among incident pre-dialysis patients managed within a french care network. *Clin Nephrol.* 2007;67(2):81-8.
- Thitiarchakul S, Tasanarong A. 12-week clinical effects of erythropoietin Espogen™ in end stage renal patients undergoing hemodialysis. *J Med Assoc Thai.* 2007;90(4):636-642.
- Thomas MC, MacIsaac R, Tsalamandris C, Power D, Jerums G. Unrecognized anemia in patients with diabetes. *Diabetes Care.* 2003;26(4):1164-1169.
- Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. *Nephrol Dial Transplant.* 1989;4:883-887.
- Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietin regimens using a computerized decision-support system: a randomized clinical study. *J Am Soc Nephrol.* 2005;16:1463-1470.
- Tonelli M, Wiebe N, Culeton B, House A, Rabbat C, Fok M, et al. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol.* 2006;17:2034-2047.
- Topf JM. CERA: third generation erythropoiesis-stimulating agent. *Expert Opin. Pharmacother.* 2008;9(5):839-849.
- Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. *Health Services Research. Health Serv Res.* 1972;7(2):118-133.
- Trachsler J, Glück Z, Dickenmann M, Gauthier T, Brünisholz M, Martin P-Y, Burnier M, Wahl C, Wüthrich RP. Parameters for successful monthly extended dosing of darbepoetin- α in patients undergoing hemodialysis. *Clin Nephrol.* 2009;71(6):697-702.
- Treatment of renal anemia. *Nephrol Dial Transplant.* 2004;19(Suppl 2):ii16-ii31.
- Trembecki J, Kokot F, Wiecek A, Marcinkowski W, Rudka R. Improved sexual function in haemodialyzed males with chronic renal failure treated with erythropoietin (rHuEPO). *Przegląd Lekarski.* 1995;52(9):462-466.
- U.S. Congress, Office of Technology Assessment, Recombinant Erythropoietin: Payment Options for Medicare, OTA-H-451 (Washington, DC: U.S. Government Printing Office, May 1990).
- U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: February 2006 draft guidance. *Health Qual Life Outcomes.* 2006;4:79.
- U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, and U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: December 2009. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>. (Accessed May 11, 2011).
- US Renal Data System, USRDS 2004 Annual Data Report: Atlas of chronic kidney disease in the united states, National Institute of Health, National Institute of Diabetes & Digestive & Kidney Disease, Bethesda, MD, 2004. (Accessed May 11, 2011).
- U.S. Renal Data System, USRDS 2008 Annual Data Report: USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease

in the United States. Chapter 5: Clinical Indicators and Preventive Health, pages 89-100. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2008. (Accessed May 11, 2011).

US Renal Data System, USRDS 2009 Annual Data Report: Atlas of chronic kidney disease in the united states, National Institute of Health, National Institute of Diabetes & Digestive & Kidney Disease, Bethesda, MD, 2009. (Accessed May 11, 2011).

U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Chapter 2: Chronic Kidney Disease Identified in the Claims Data, pages 53-64. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010 (Accessed May 11, 2011).

Udayaraj U, Tomson CR, Gilg J, Ansell D, Fogarty D. UK renal registry 11th annual report: chapter 6 Comorbidities and current smoking status amongst patients starting renal replacement therapy in England, Wales, and northern Ireland: national and centre-specific analyses. *Nephron Clin Pract.* 2009;111(s1):c97-111.

Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. *Clin Pharmacol Ther.* 1992;51:76-89.

Usberti M, Gerardi G, Bufano G, Tira P, Micheli A, Albertini A, et al. Effects of erythropoietin and vitamin E-modified membrane on plasma oxidative stress markers and anemia of hemodialyzed patients. *Am J Kidney Dis.* 2002;40(3):590-599.

Van Campenhout A, Van Campenhout C, Lagrou A, Manuel-y-Keenoy B. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. *Biometals.* 2008;21:159-170.

Van der Meer P, Lok DJ, Januzzi JL, Bruggink-Andre de la Porte PW, Lipsic E, van Wijngaarden J, et al. Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. *Eur Heart.* 2008.

Van der Putten K, Braam B, Jie KE, Gaillard CA. Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure. *Nat Clin Pract.* 2008;4(1):47-57.

Van der Putten K, Jie KE, van den Broek D, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, Braam B, Gaillard CA. Hecidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. *Eur J Heart Fail.* 2010;12:943-950.

Van der Putten K, Van der Baan FH, Schellekens H, Gaillard CAJM. Hemoglobin variability in patients with chronic kidney disease in the Netherlands. *Int J Artif Organs.* 2009;32:787-793.

Van Dyke DC, Layrisse M, Lawrence JH, Garcia JF, Pollycove M. Relation between severity of anemia and erythropoietin titer in human beings. *Blood.* 1961;18:187-201.

Van Iperen CE, Gaillard CAJM, Kraaijenhagen RJ, Braam BG, Marx JJM, van de Wiel A. Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. *Crit Care Med.* 2000;28(8):2773-2779.

Van Stone JC. Who should receive recombinant human erythropoietin? *Semin Nephrol.* 1989;9(1) suppl 2:3-7.

Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. *Nephrol Dial Transplant.* 2004;19:561-565.

Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. *Kidney Int.* 2005;68(6):2846-2856.

Valderrábano F. Quality of life benefits of early anaemia treatment. *Nephrol Dial Transplant.* 2000;15[Suppl 3]:23-28.

Valderrábano F, Hörl WH, Macdougall IC, Rossert j, Rutkowski B, Wauters J. PRE-dialysis survey on anaemia management. *Nephrol Dial Transplant.* 2003;18(1):89-100.

Vanasse GJ, Berliner N. Anemia in elderly patients: an emerging problem for the 21st century. *Hematology.* 2010:271-275.

Vanrenterghem Y, Bárány P, Mann JFE, Kerr PG, Wilson J, Baker NF, Gray SJ. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. *Kidney Int.* 2002;62:2167-2175.

Vanrenterghem Y, Waer M, Roels L, Coosemans W, Christaens M, Opelz G. A prospective, randomized trial of pretransplant blood transfusions in cadaver kidney transplant candidates. *Transplant Int.* 1994; 7(Suppl 1):S243-S246.

Vaziri ND, Ritchie C, Brown P, Kaupke J, Atkins K, Barker S, Hyatt J. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. *ASAIO Trans.* 1989;35:505-508.

Vaziri ND, Kaupke CJ, Barton CH, Gonzalez E. Plasma concentration and urinary excretion of erythropoietin in adult nephritic syndrome. *American Journal of Medicine.* 1992;92:3540.

Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. *Semin Nephrol.* 2004;24:469-473.

Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. *Am J Nephrol.* 1992;12:68-72.

Vigano G, Benigni A, Medogni D, Mingaardi G, Mecca G, Remuzzi G. Recombinant human erythropoietin to correct uremic bleeding. *Am J Kidney Dis.* 1991;18(1):44-49.

- Vincent J, Spapen H, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, et al. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial. *Crit Care Med*. 2006;34(6):1661-1667.
- Virot JS, Janin G, Guillaumie J, Michel P, Dubot P, Chevet D, Rifle G. Must erythropoietin be injected by the subcutaneous route for every hemodialyzed patient? *Am J Kidney Dis*. 1996;28(3):400-408.
- Vlahakos DV, Marathias KP, Madias NE. The role of the rennin-angiotensin system in the regulation of erythropoiesis. *Am J Kidney Dis*. 2010;56(3):558-565.
- Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai C, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med*. 2008;359:242-251.
- Walker RG, Strippoli GF. A pegylated epoetin in anaemia of renal disease: non-inferiority for an unvalidated surrogate. *Lancet*. 2007;370(9596):1395-1396.
- Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. *Kidney Int*. 1987;31:1205-1209.
- Wallner SF, Kurnick JE, Ward HP, Vautrin R, Alfrey AC. The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis. *Blood*. 1976;47(4):561-569.
- Wallner SF, Vautrin RM, Kurnick JE, Ward HP. The effect of serum from patients with chronic renal failure on erythroid colony growth in vitro. *J Lab Clin Med*. 1978;92(3):370-375.
- Walls J. Haemoglobin-is more better? *Nephrol Dial Transplant*. 1995;10(Suppl 2): 56-61.
- Wang O, Kilpatrick RD, Critchlow CW, Ling X, Bradbury BD, Gilbertson DT, et al. Relationship between epoetin alfa dose and mortality: findings from a marginal structural model. *Clin J Am Soc Nephrol*. 2010;5:182-188.
- Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anaemia: the search for the elusive transfusion trigger. *Vox Sang*. 2010;98:2-11.
- Wann-Hansson C, Kleivsgård R, Hagell P. Cross-diagnostic validity of the Nottingham health profile index of distress (NHPD). *Health and Qual Life Outcomes*. 2008;6:47.
- Ward HJ, Sun CH, Paul WL, Koyle MA, Yanagawa N, Lee DBN. Erythropoietin in renal transplant recipients: studies based on recombinant human erythropoietin radioimmunoassay. *Transplant Proc*. 1989;21(1):2041-2042.
- Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) Conceptual Framework and item selection. *Med Care*. 1992;30(6):473-483.
- Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. *Semin Nephrol*. 1989;9(1)(Suppl 1):30-34.
- Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. *Am J Med*. 1990;89:432-435.
- Weber WW. Pharmacogenetics: from description to prediction. *Clin Lab Med*. 2008;28:499-511.
- Wei M, Bargman JM, Oreopoulos DG. Factors related to erythropoietin hypo-responsiveness in patients on chronic peritoneal dialysis. *Int Urol Nephrol*. 2007;39:935-940. Pub 2007 May 30.
- Weiner DE, Miskulin DC. Anemia management in chronic kidney disease: bursting the hemoglobin bubble. *Ann Intern Med*. 2010;153:53-55. E pub 2010 May 3.
- Weinhandl ED, Peng Y, Gilbertson DT, Bradbury BD, Collins AJ. Hemoglobin variability and mortality: confounding by disease severity. *Am J Kidney Dis*. 2011;57(2):255-265.
- Weir MR. Medical management of kidney transplantation. In: Norman DJ, Turka LA, eds. *Primer on Transplantation*. Philadelphia: Lippincott Williams; 2005.
- Weiss LG, Clyne N, Fihlho JD, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β : results from a randomized controlled multicentre trial. *Nephrol Dial Transplant*. 2000;15(12):2014-2019.
- Weiss G, Goodnough LT. Anemia of chronic disease. *N Engl J Med*. 2005;352:1011-1023.
- Wells AW, Llewelyn CA, Casbard A, Johnson AJ, Amin M, Ballard S, et al. The EASTR study: indications for transfusion and estimates of transfusion recipient numbers in hospitals supplied by the National Blood Service. *Transfus Med*. 2009;19(6):315-328.
- Wernig G, Mercher T, Okabe R, Levine RL, Lee BH, Gilliland G. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. *Blood*. 2006;107(11):4274-4278. E pub 2006 Feb 14
- Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, van der Harst P, et al. Bone marrow dysfunction in chronic heart failure patients. *Eur J Heart Fail*. 2010;12(7):676-684.
- Williams AJ, Ford D, Casula A, Tomson CR. UK renal registry 11th annual report: chapter 8 adequacy of haemodialysis in UK renal centres in 2007: national and centre-specific analyses. *Nephron Clin Pract*. 2009;111(suppl 1): c141-c147. E pub 2009 March 26
- Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. *Am J Kidney Dis*. 1995;25(3):433-439.

Wizemann V, Brune T, Kramer W, Schäfer R, Schütterle G. Recombinant human erythropoietin expressed in C-127 mouse cells: efficacy, side-effects and cardiovascular actions. *Nephrol Dial Transplant*. 1991;6 Suppl 2:122-125.

Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. *Curr Med Res Opin*. 2008;24(3):625-637.

Wolff M, Jelkmann W. Erythropoiesis and erythropoietin levels in renal transplant recipients. *Klin Wochenschr*. 1991;69(2):53-58.

Wood DM, Thomson AH, Lawes M, Jones AL, Dargan PI. Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. *The Drug Monit*. 2005;27(4):405-408.

Woodburn KW, Schatz PJ, Fong K-L, Beaumier P. Erythropoiesis equivalence, pharmacokinetics and immune response following repeat hematide™ administration in cynomolgus monkeys. *Int J Immunopathol Pharmacol*. 2010;23(1):121-129.

Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW, Dower WJ. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. *Nat Biotechnol*. 1997;15(12):1261-1265.

Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. *J Am Soc Nephrol*. 1999;10(6):1309-1316.

Yagil Y. Proposed therapeutic algorithm for the treatment of anemia of chronic renal failure in pre-dialysis patients with low dose once weekly subcutaneous r-HuEPO. *Isr J Med Sci*. 1997;33(1):36-44.

Yamazaki T, Kanzaki M, Kamidono S, Fujisawa M. Effect of erythropoietin on Leydig cell is associated with the activation of Stat5 pathway. *Mol Cell Endocrinol*. 2004;213:193-198.

Yang S, Kuo P, Wang J, Lin M, Su S. Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL_BREF (TW). *Am J Kidney Dis*. 2005;46(4):635-641.

Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. *Am J Kidney Dis*. 2002;40(6):1111-1121.

Yorioka N. Recombinant human erythropoietin increases interleukin-1 β production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy. *Nephron*. 1994;67(2):245-247.

Yu AW, Leung CB, Li PKT, Lui SF, Lai KN. Pain perception following subcutaneous injections of citrate-buffered and phosphate-buffered epoetin alpha. *Int J Artif Organs*. 1998;21(6):341-343.

Yu JM, Shord SS, Cuellar S. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia. *J Oncol Pharm Pract*. 2010;1-6.

Yuen D, Richardson RMA, Fenton SSA, McGrath-Chong ME, Chan CT. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. *ASAIO J*. 2005;51:236-241.

Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. *Kidney Int*. 2004;66:144-156.

Zachée P, Ferrant A, Daelemans R, Coolen L, Goossens W, Lins RL, Couttenye M, De Broe ME, Boogaerts MA. Oxidative injury to erythrocytes, cell rigidity the splenic hemolysis in hemodialyzed patients before and during erythropoietin treatment. *Nephron*. 1993;65:288-293.

Zadražil J, Horák P, Horčíčka V, Zahálková J, Štrébl P, Hruby M. Endogenous erythropoietin levels and anemia in long term renal transplant recipients. *Kidney Blood Press Res*. 2007;30(2):108-116. E pub 2007 Mar 19

Zanen AL, Adriaansen HJ, van Bommel EFH, Posthuma R, de Jong GMT. 'Oversaturation' of transferring after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. *Nephrol Dial Transplant*. 1996;11(5):820-824.

Zappacosta AR, Caro J, Erslev A. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. *Am J Med*. 1982;72(1):53-57.

Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? *CMAJ*. 2008;179(4):333-337.

Zehnder C. Erythropoietin treatment: influence of haemoglobin concentration on dialyser creatinine clearance in haemodialysed patients. *Nephron*. 1989;51:424-425.

Zehnder C, Blumberg A. The treatment of anemia of hemodialysis patients. *Schweiz Med Wochenschr*. 1990;120(7):217-220.

Zehnder C, Blumberg A. Recombinant human erythropoietin in anemic patients on maintenance hemodialysis: comparison between intravenous and subcutaneous administration. *Nephron*. 1991;57:485-486.

Zeier M, Jones E, Ritz E. Autosomal dominant polycystic kidney disease-the patient on renal replacement therapy. *Nephrol Dial Transplant*. 1996;11[Suppl 6]:18-20.

Zhang Y, Thamer M, Cotter D, Kaufmann J, Hernán MA. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. *Clin J Am Soc Nephrol*. 2009;4:638-644.

Zhang Y, Thamer M, Kaufman J, Cotter D, Hernan MA. Effect of epoetin dose on mortality and cardiovascular outcomes among elderly hemodialysis patients with diabetes. *Kidney Int*. 2011;in press.

Zhang Y, Thamer M, Stefanik K, Kaufman J, Cotter DJ. Epoetin requirements predict mortality in hemodialysis patients. *Am J Kidney Dis*. 2004;44(5):866-

Zou S, Dorsey KA, Notari EP, Foster GA, Krysztof DE, Musavi F, Dodd RY, Stramer SL. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. *Transfusion*. 2010;50:1495-1504.

Zwezdaryk KJ, Coffelt SB, Figueroa YG, Liu J, Phinney DG, LaMarca HL, et al. *Exp Hematol*. 2007;35:640-652.